

CITATION REPORT

List of articles citing

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

DOI: 10.1200/jco.2007.15.0375

Journal of Clinical Oncology, 2008, 26, 3543-51.

Source: <https://exaly.com/paper-pdf/44522214/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2268	.		
2267	Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions. 2008 , 9, 300-12		4
2266	Das fortgeschrittene nichtkleinzellige Lungenkarzinom. 2008 , 3, 26-36		
2265	Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. 2008 , 9, 249-51		5
2264	Adjuvant chemotherapy for resected non-small cell lung cancer. 2008 , 20, 198-203		10
2263	Chemotherapy for advanced stage non-small cell lung cancer. 2008 , 20, 210-6		18
2262	Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. 2008 , 9, 1135-42		65
2261	Personalized medicine in advanced non-small-cell lung cancer: reality or wishful thinking?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5651; author reply 5651-2	2.2	
2260	First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3485-6	2.2	47
2259	Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. 2009 , 39, 27-32		32
2258	In Reply. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5651-5652	2.2	
2257	Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. 2008 , 3, e3695		99
2256	Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. 2009 , 2, 21-37		
2255	Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. 2009 , 5, 781-7		6
2254	Efficacy of Pemetrexed in Relapsed Non-Small Cell Lung Cancer and Thymidylate Synthase Expression. 2009 , 67, 191		5
2253	Optimizing the management of advanced non-small-cell lung cancer: a personal view. 2009 , 16, 9-21		28
2252	Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study. 2009 , 2009, 457418		3

2251	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. 2009 , 2, 209-17		12
2250	Lung cancer: current diagnosis and treatment. 2009 , 106, 809-18; quiz 819-20		46
2249	Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue. 2009 , 9, 1455-65		1
2248	Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3836-41	2.2	150
2247	Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4787-92	2.2	136
2246	Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5248-54	2.2	51
2245	Integration of molecular profiling into the lung cancer clinic. 2009 , 15, 5317-22		73
2244	A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. 2009 , 17, 206-18		78
2243	Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3217-24	2.2	229
2242	invited abstracts. 2009 , 20, v7-v12		
2241	Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. 2009 , 20, 1249-56		52
2240	Non-small-cell lung cancer: should histology guide chemotherapy treatment?. 2009 , 20, 1608-1609		1
2239	Current treatments for advanced stage non-small cell lung cancer. 2009 , 6, 233-41		113
2238	Pemetrexed for the treatment of non-small-cell lung cancer. 2009 , 9, 1195-209		11
2237	Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. 2009 , 14, 137-47		45
2236	Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. 2009 , 14, 930-5		57
2235	Angiogenesis inhibitors in the treatment of non-small cell lung cancer. 2009 , 1, 95-107		6
2234	Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, e141-2; author reply e143-4	2.2	37

2233	Evolution of therapy decision-making process for advanced non-small cell lung cancer. 2009 , 77 Suppl 1, 97-102		1
2232	Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. 2009 , 4, 1404-14		32
2231	Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. 2009 , 4, S1029-39; quiz S1041-2		36
2230	Update in lung cancer 2008. 2009 , 179, 860-8		34
2229	Adjuvant therapy for resected non-small cell lung cancer. 2009 , 1, 109-18		6
2228	The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. 2009 , 4, 1568-71		37
2227	Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. 2009 , 136, 701-709		91
2226	Pemetrexed approved for use in first-line treatment of most common lung cancer. 2009 , 1, 77-77		
2225	Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. 2009 , 4, 1280-8		48
2224	Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. 2009 , 16, 3919-30		12
2223	New avenues for second-line treatment of metastatic non-small-cell lung cancer. 2009 , 9, 115-24		9
2222	The drug targeting and delivery approach applied to Pt-antitumour complexes. A coordination point of view. 2009 , 16, 4544-80		60
2221	Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. 2009 , 20, 850-6		12
2220	First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. 2009 , 9, 425-35		23
2219	Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. 2009 , 180, 769-79		84
2218	Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2516-22	2.2	228
2217	EML4-ALK: honing in on a new target in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4232-5	2.2	258
2216	Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3277-83	2.2	170

2215	Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure?. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3268-70	2.2	8
2214	Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. 2009 , 15, 7547-7552		60
2213	Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3284-9	2.2	139
2212	Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemo-naïve patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. 2009 , 15, 382-9		14
2211	PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. 2009 , 10, 193-8		47
2210	Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009. 2009 , 10, 217-222		
2209	Highlights From: The 13th World Conference on Lung Cancer San Francisco, CA July 31-August 4, 2009. 2009 , 10, 317-321		
2208	Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. 2009 , 10, 392-4		16
2207	Lung cancer outcomes in women. 2009 , 36, 532-41		13
2206	A technique to improve diagnostic information from fine-needle aspirations: immunohistochemistry on cytoscope. 2009 , 117, 120-7		6
2205	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). 2009 , 11, 284-9		12
2204	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. 2009 , 11, 428-36		4
2203	Dramatic complete response in patient with lung adenocarcinoma. 2009 , 11, 851-3		1
2202	Therapeutic uses of topotecan for thoracic malignancies. 2009 , 3, 125-131		
2201	NSCLC in the elderly--the legacy of therapeutic neglect. 2009 , 10, 180-94		9
2200	Abstracts 2009. 2009 , 10, 1-213		
2199	Non-small cell lung cancer ASCO 2009. 2009 , 2, 202-205		
2198	Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. 2009 , 64, 233-41		17

2197	Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer. 2009 , 64, 385-90		2
2196	Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. 2009 , 64, 917-24		3
2195	Reinforcement learning design for cancer clinical trials. 2009 , 28, 3294-315		130
2194	Pulmonary adenocarcinomas: classification and reporting. 2009 , 54, 12-27		91
2193	Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. 2009 , 22, 709-17		85
2192	A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. 2009 , 22, 1032-43		80
2191	Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. 2009 , 28 Suppl 1, S4-13		56
2190	Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. 2009 , 101, 225-31		43
2189	Molecular Biomarkers in Non-small Cell Lung Cancer [pointing the way to better outcomes from treatment. 2009 , 5, 213-214		
2188	Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. 2009 , 33, 73-111		17
2187	Pharmacogenomics in non-small-cell lung cancer chemotherapy. 2009 , 61, 408-17		24
2186	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6251-66	2.2	619
2185	VEGF kinase inhibitors: how do they cause hypertension?. 2009 , 297, R1-5		55
2184	Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5080-7 ²		191
2183	Pemetrexed in first-line treatment of non-small cell lung cancer. 2009 , 35, 364-73		25
2182	Positioning pemetrexed in the treatment of ovarian cancer. 2009 , 45, 1330-2		2
2181	Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study. 2009 , 45, 2298-303		37
2180	Palliative chemotherapy: do we need yet another end-point?. 2009 , 45, 2234-5		2

2179	Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. 2009 , 64, 308-13	37
2178	Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. 2009 , 64, 124-6	6
2177	Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. 2009 , 66, 338-43	14
2176	Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features. 2009 , 65, 385-7	8
2175	Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report. 2009 , 65, 251-3	7
2174	Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. 2009 , 65, 383-4	14
2173	Pemetrexed in the treatment of advanced non-squamous lung cancer. 2009 , 66, 141-9	40
2172	Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. 2009 , 18, 1197-218	180
2171	Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer. 2009 , 69, 2279-302	23
2170	A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer. 2009 , 9, 155-60	2
2169	Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. 2009 , 10, 148-50	17
2168	Advanced non-small-cell lung cancer in the elderly. 2009 , 10, 158-67	9
2167	Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. 2009 , 10, 252-6	57
2166	Cancer treatments: can we find treasures at the bottom of the sea?. 2009 , 10, 295-300	21
2165	Pemetrexed-induced pneumonitis: a case report. 2009 , 10, 364-6	8
2164	Updated clinical information on multitargeted antifolates in lung cancer. 2009 , 10 Suppl 1, S35-40	23
2163	Novel targeted agents for lung cancer. 2009 , 10 Suppl 1, S41-6	9
2162	Pemetrexed : première chimiothérapie histoguidée dans le CBNPC. 2009 , 1, S40-S44	

2161	Prise en charge des cancers bronchiques non ^ petites cellules au stade m̃tastatique : volution du traitement de premĩre ligne. 2009 , 1, 401-414		
2160	Chemotherapy for lung cancer: the state of the art in 2009. 2009 , 9, 1365-78		36
2159	Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. 2009 , 69, 5467-74		125
2158	Analisi di costo-efficacia di pemetrexed pi c̃isplatino versus gemcitabina pi c̃isplatino nel trattamento di prima linea in pazienti con NSCLC non squamoso in stadio avanzato. 2009 , 2, 73-80		1
2157	Analisi di costo-efficacia nel trattamento di prima linea con i regimi chemioterapici pemetrexed pi c̃isplatino, gemcitabina pi c̃isplatino e bevacizumab pi gemcitabina pi c̃isplatino in pazienti con NSCLC localmente avanzato o metastatizzato in Italia. 2009 , 2, 99-109		
2156	The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. 2009 , 14, 253-63		591
2155	Novel therapies in metastatic head and neck squamous cell carcinoma. 2009 , 6, 310-316		1
2154	Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6229-36	2.2	77
2153	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. 2009 , 10, 1102-10		21
2152	Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal. 2009 , 10, 1031-2		5
2151	Reclassifying bronchial-pulmonary carcinoma: Differentiating histological type in biopsies by immunohistochemistry. 2009 , 15, 1101-1119		8
2150	Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. 2009 , 374, 1432-40		926
2149	Gefitinib in the treatment of advanced non-small-cell lung cancer. 2009 , 9, 401-12		17
2148	Controverse. Le traitement des CBNPC guid^par l^histologie : et si le crit̃re choisi n^ait pas le bon ?. 2009 , 65, S19-S24		
2147	Chimioth̃rapie p̃i-op̃ratoire des cancers bronchiques non ^ petites cellules. 2009 , 1, 365-375		
2146	Les grandes tapes de la personnalisation des traitements en oncologie. 2009 , 1, S3-S8		
2145	Chemotherapy in the older patient with operable non-small cell lung cancer: neoadjuvant and adjuvant regimens. 2009 , 19, 377-89		3
2144	Cas clinique n^4 propos^par l^quipe de Lyon. 2009 , 65, 19-22		

2143	[Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study]. 2009 , 26, 952-60	5
2142	[Towards a histologically guided management for NSCLC]. 2009 , 26, 1097-106	0
2141	Traitement histo-guidé des cancers bronchiques non à petites cellules : pour. 2009 , 65, S16-S18	
2140	Quoi de neuf dans les facteurs biologiques prédictifs de l'efficacité de la chimiothérapie ?. 2009 , 65, S54-S60	
2139	[First-line chemotherapy for metastatic non-small cell carcinoma: what are the options]. 2009 , 26, 1091-6	0
2138	Le cetuximab en 1re ligne de traitement dans les CBNPC. 2009 , 65, H19-H21	
2137	Histology-based treatment: a new scenario in the management of advanced nonsmall cell lung cancer. 2009 , 21, 97-8	3
2136	Treatment of Advanced Lung Cancer. 2009 , 16, 157-171	2
2135	Nonsmall cell lung cancer in never smokers. 2009 , 21, 99-104	52
2134	Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patients. 2009 , 15, 346-54	11
2133	Results of cutting-edge surgery in stage IIIA-N2 nonsmall cell lung cancer. 2009 , 21, 105-9	6
2132	Beyond anti-epidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. 2009 , 21, 116-23	10
2131	Non-small-cell lung cancer: targeted therapies. 2009 , 6, 95-98	
2130	Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. 2009 , 4, 326-32	88
2129	Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009). 2009 , 4, 1293-300	3
2128	Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. 2009 , 4, 243-50	43
2127	Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. 2009 , 4, 1202-11	58
2126	A phase I study of TS-1 plus carboplatin in patients with advanced non-small-cell lung cancer. 2009 , 21, 80-5	2

2125	Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial. 2009 , 21, 439-44	4
2124	Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. 2009 , 136, 1112-1118	36
2123	Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. 2009 , 4, 1524-9	70
2122	A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer. 2009 , 4, 1144-7	4
2121	The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. 2009 , 4, 792-801	329
2120	Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. 2009 , 4, 1537-43	47
2119	Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. 2009 , 4, 862-8	38
2118	Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. 2009 , 4, 1148-55	20
2117	Survival prognostication in non-small cell lung cancer. 2009 , 4, 785-6	1
2116	Current approach to treatment of non-small cell lung cancer in developing countries--time for a rethink?. 2009 , 4, 143-4	7
2115	Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. 2009 , 4, 1530-6	26
2114	Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer. 2009 , 4, 1170-3	1
2113	Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. 2009 , 4, 1117-25	32
2112	Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. 2009 , 4, 1083-93	91
2111	Reclassificaço do carcinoma broncopulmonar: Diferenciaço do tipo histolgico em bipsias por imuno-histoqumica. 2009 , 15, 1101-1119	10
2110	Recent developments of targeted therapies in the treatment of non-small cell lung cancer. 2009 , 6, 91-102	24
2109	Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. 2010 , 21, 799-804	9
2108	Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. 2010 , 11, 85-94	8

2107	Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. 2010 , 5, 688-95	36
2106	The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma features. 2010 , 11, 74-7	5
2105	The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer. 2010 , 11, 58-60	4
2104	Role of pemetrexed and platinum combination in patients with non-small cell lung cancer. 2010 , 11, 29-36	4
2103	The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). 2010 , 11, 67-73	29
2102	Predictive markers for haematological toxicity of pemetrexed. 2010 , 11, 48-57	9
2101	The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer. 2010 , 11, 61-6	4
2100	Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. 2010 , 5, 1977-85	47
2099	A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. 2010 , 5, 1630-6	135
2098	Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer. 2010 , 3, 34-8	1
2097	Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. 2010 , 5, 510-6	137
2096	First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. 2010 , 5, 260-74	195
2095	A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. 2010 , 21, 777-84	16
2094	Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. 2010 , 16, 315-20	10
2093	Initial evaluation of the nonsmall cell lung cancer patient: diagnosis and staging. 2010 , 16, 307-14	23
2092	Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography. 2010 , 25, 142-50	19
2091	The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. 2010 , 11, 37-47	39
2090	Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. 2010 , 5, 484-90	16

2089	Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. 2010 , 5, 436-41	172
2088	A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. 2010 , 5, 1821-5	12
2087	Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. 2010 , 5, 1001-10	92
2086	Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. 2010 , 5, 1143-51	38
2085	Non-small cell lung cancer. 2010 , 8, 740-801	457
2084	1. Pemetrexed (Alimta®). 2010 , 99, 1597-1604	
2083	[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer]. 2010 , 54, 137-43	
2082	Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer. 2010 , 5, 1602-8	8
2081	Novel taxanes/epothilones. 2010 , 5, S490-1	1
2080	A multi-institution phase I/II trial of triweekly regimen with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. 2010 , 5, 702-6	21
2079	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. 2010 , 5, 1424-9	26
2078	Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancer-special reference to tumor size. 2010 , 5, 45-8	15
2077	Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. 2010 , 5, 1815-20	22
2076	Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. 2010 , 5, 369-75	35
2075	Prognostic impact of node involvement pattern in pN1 non-small cell lung cancer patients. 2010 , 5, 1576-82	7
2074	Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. 2010 , 5, 1963-9	32
2073	Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. 2010 , 5, 411-4	144
2072	Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. 2010 , 5, 719-20	34

2071	Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. 2010 , 5, 442-7	184
2070	Maintenance therapy in advanced non-small cell lung cancer. 2010 , 5, 723-34	15
2069	A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status. 2010 , 5, 158-68	10
2068	Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer. 2010 , 5, 841-5	7
2067	Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. 2010 , 5, 1894-904	50
2066	Time trends of surgical outcome in patients with non-small cell lung cancer. 2010 , 5, 825-9	35
2065	Differences of gene expression in non-small cell lung cancer: are histology, tumor site, and methodology relevant?. 2010 , 5, 1310-1; author reply 1311	1
2064	Serum concentrations of Erlotinib at a dose of 25 mg daily. 2010 , 5, 1311-2	6
2063	Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. 2010 , 8, 822-32	31
2062	Toxicity and Response of Pemetrexed Plus Carboplatin or Cisplatin with Concurrent Chest Radiation Therapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Phase I Trial. 2010 , 5, 1391-1396	7
2061	Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. 2010 , 5, 275-9	54
2060	Lung adenocarcinoma: lessons in translation from bench to bedside. 2010 , 77, 597-605	30
2059	Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. 2010 , 66, 547-58	17
2058	A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. 2010 , 66, 861-8	10
2057	Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. 2010 , 66, 611-7	28
2056	Die Prim�rtherapie des nichtkleinzelligen Lungenkarzinoms. 2010 , 24, 97-104	
2055	The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients. 2010 , 136, 547-52	5
2054	Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. 2010 , 15, 583-7	14

2053	Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases. 2010 , 9, 502-506	2
2052	Impact of biomarkers on non-small cell lung cancer treatment. 2010 , 5, 5-17	14
2051	Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. 2010 , 5, 231-5	10
2050	Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality. 2010 , 5, 229-30	
2049	Biomarkers in bronchopulmonary cancer. 2010 , 12, 92-9	3
2048	Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. 2010 , 12, 521-5	9
2047	Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience. 2010 , 12, 686-91	3
2046	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. 2010 , 12, 735-41	11
2045	UFT and S-1 for treatment of primary lung cancer. 2010 , 58, 3-13	16
2044	Biomarkers for Therapies Directed at Angiogenesis. 2010 , 6, 133-143	4
2043	Molecular testing in lung cancer: the time is now. 2010 , 12, 335-48	18
2042	Cancer of unknown primary site. 2010 , 37, 71-9	22
2041	Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemo-naïve patients with advanced non-small-cell lung cancer. 2010 , 11, 105-13	19
2040	The emerging role of biomarkers in advanced non-small-cell lung cancer. 2010 , 11, 149-59	18
2039	Extended-duration therapy in advanced non-small-cell lung cancer: promise and pitfalls. 2010 , 11, 383-90	1
2038	Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma. 2010 , 11, 412-22	6
2037	Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. 2010 , 10, 26	20
2036	In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. 2010 , 10, 441	12

2035	[Study of use of pemetrexed in non-small cell lung cancer]. 2010 , 34, 194-203	2
2034	Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. 2010 , 116, 670-5	84
2033	Implications of key trials in advanced nonsmall cell lung cancer. 2010 , 116, 1155-64	13
2032	Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423. 2010 , 116, 2382-9	3
2031	Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. 2010 , 126, 1895-1902	44
2030	Thymidylate synthase expression in high-grade neuroendocrine and non-small cell lung cancer histotypes--is it ready for primetime?. 2010 , 102, 10	1
2029	The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. 2010 , 102, 856-62	17
2028	Surgical management of non-small cell lung cancer with mediastinal lymphadenopathy. 2010 , 22, 325-33	6
2027	Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. 2010 , 75, 173-234	147
2026	Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. 2010 , 11, 167	24
2025	Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. 2010 , 101, 161-6	99
2024	ABCC11/MRP8 confers pemetrexed resistance in lung cancer. 2010 , 101, 2404-10	37
2023	AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. 2010 , 17, 1042-51	39
2022	Anti-angiogenesis drugs in lung cancer. 2010 , 15, 387-92	7
2021	Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. 2010 , 17, 13-23	26
2020	Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). 2010 , 4, 81-98	34
2019	Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients. 2010 , 1, 85-100	5
2018	Maintenance therapy for metastatic non-small-cell lung cancer - the role of pemetrexed. 2010 , 1, 1-7	

2017	Refining the treatment of advanced nonsmall cell lung cancer. 2010 , 1, 9-22	1
2016	Gene expression-based classification of non-small cell lung carcinomas and survival prediction. 2010 , 5, e10312	543
2015	The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. 2010 , 5, e12209	41
2014	Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer. 2010 , 1, 51-55	4
2013	Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. 2010 , 2010, 597098	14
2012	Cancer chemotherapy: targeting folic acid synthesis. 2010 , 293	8
2011	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. 2010 , 2, 143-56	19
2010	Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC). 2010 , 11, 12-28	13
2009	Pemetrexed: potential role in the adjuvant chemotherapy of non-small cell lung cancer. 2010 , 11, 78-84	3
2008	The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer. 2010 , 1, 101-106	
2007	Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer. 2010 , 1, 53-62	
2006	The role of pemetrexed combined with targeted agents for non-small cell lung cancer. 2010 , 11, 2-11	5
2005	Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. 2010 , 25, 294-300	23
2004	Treatment of Non-Small Cell Lung Cancer: Focus on Pemetrexed Disodium. 2010 , 2, CMT.S5262	
2003	The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma. 2010 , 2, CMT.S1166	
2002	Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). 2010 , 21, 1804-1809 ⁴⁸⁵	
2001	Lung cancer: multidisciplinary approach for management: cell and molecular biology assembly contribution to the celebration of 20 years of the ERS. 2010 , 35, 717-20	8
2000	Consequences of targeted treatments for second-line therapy. 2010 , 21 Suppl 7, vii234-40	4

1999	Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. 2010 , 14 Suppl 1, 47-53		26
1998	Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1843-9	2.2	147
1997	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. 2010 , 16, 5873-82		168
1996	The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. 2010 , 6, 1827-32		19
1995	A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. 2010 , 16, 2450-7		193
1994	Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1835-42	2.2	379
1993	Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. 2010 , 16, 2496-504		27
1992	Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). 2010 , 15, 1352-8		45
1991	ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. 2010 , 21, 1817-1824		55
1990	Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer. 2010 , 56, 353-8		5
1989	Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2167-73	2.2	62
1988	Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection. <i>Journal of Clinical Oncology</i> , 2010 , 28, e131; author reply e132	2.2	2
1987	Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3138-45	2.2	228
1986	Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. <i>Journal of Clinical Oncology</i> , 2010 , 28, e482-3; author reply e484	2.2	4
1985	What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. 2010 , 2, 229-35		3
1984	Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?. 2010 , 2010, 524629		6
1983	A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIB or IV non-small cell lung cancer in China. 2010 , 56, 472-7		6
1982	Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. 2010 , 21, 2227-2232		86

1981	Current and emerging therapies for patients with advanced non-small-cell lung cancer. 2010 , 67, S9-14		11
1980	Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. 2010 , 15, 1102-12		56
1979	Clinical Management of Lung Cancer. 2010 , 437-445		
1978	If histology matters. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1810-2	2.2	10
1977	Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. 2010 , 70, 10299-309		76
1976	Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. 2010 , 181, 181-8		37
1975	How to integrate current knowledge in selecting patients for first line in NSCLC?. 2010 , 21 Suppl 7, vii230-3		5
1974	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v116-9		236
1973	Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. 2010 , 15, 436-46		49
1972	Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. 2010 , 11, 1683-93		7
1971	Personalized medicine for non-small-cell lung cancer. 2010 , 10, 1601-11		10
1970	The evolving role of histology in the management of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5311-20	2.2	220
1969	Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5240-6	2.2	136
1968	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. <i>Journal of Clinical Oncology</i> , 2010 , 28, 911-7.2		368
1967	MicroRNA expression differentiates histology and predicts survival of lung cancer. 2010 , 16, 430-41		283
1966	Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5116-23	2.2	58
1965	Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5046-53	2.2	15
1964	Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. 2010 , 21, 556-561		41

1963	Lung cancer working group report. 2010 , 40 Suppl 1, i7-12		17
1962	Pemetrexed safety and pharmacokinetics in patients with third-space fluid. 2010 , 16, 2872-80		19
1961	An important recent development in cancer research has been the identification of new genetic and molecular tumor profiling techniques. Introduction. 2010 , 67, S1-2		
1960	Prognostic significance of OCT4 expression in adenocarcinoma of the lung. 2010 , 40, 961-6		40
1959	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. 2010 , 10, 180-90		16
1958	Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1534-9	2.2	136
1957	Histology matters: individualizing treatment in non-small cell lung cancer. 2010 , 15, 3-5		22
1956	Can a decisional algorithm be used in first-line treatment of advanced nonsmall cell lung cancer?. 2010 , 22, 77-8		
1955	Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. 2010 , 5, 1416-23		123
1954	[Prevention, diagnosis, therapy, and follow-up of lung cancer]. 2010 , 64 Suppl 2, e1-164		85
1953	[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?]. 2010 , 64, 727-35		2
1952	Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. 2010 , 6, 741-67		18
1951	The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. 2010 , 17, 1030-8		22
1950	Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature. 2010 , 6, 1937-40		1
1949	Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer. 2010 , 15, 1034-42		19
1948	Cisplatin plus gemcitabine for biliary tract cancer. 2010 , 363, 192; author reply 192-3		6
1947	Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. 2010 , 10, 549-57		1
1946	Advances in diagnostic bronchoscopy. 2010 , 182, 589-97		47

1945	Novel agents in the management of lung cancer. 2010 , 17, 4291-325	16
1944	Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. 2010 , 4, 499-508	5
1943	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. 2010 , 11, 2363-89	18
1942	[New classification of pulmonary cancer: application to small size biopsy sampling]. 2010 , 30, 60-3	1
1941	[Which type of diagnostic and pretreatment sampling should be chosen and for which patient?]. 2010 , 30, 64-6	1
1940	Aspects médico-économiques de la pneumologie. 2010 , 2, 205-222	
1939	Oncologie thoracique. 2010 , 2, 167-177	1
1938	New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. 2010 , 55, 22-5	9
1937	La stratégie de maintenance en première ligne de traitement dans les cancers bronchiques non ^ petites cellules avancés. 2010 , 2, 286-297	
1936	Ciblage thérapeutique du cancer pulmonaire non ^ petites cellules (CPNPC) : (encore) des promesses?. 2010 , 2, 524-526	
1935	Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: a survey of the Italian Association of Thoracic Oncology (AIOT). 2010 , 67, 339-42	4
1934	Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICO trial. 2010 , 68, 94-8	6
1933	Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. 2010 , 68, 264-8	86
1932	The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer. 2010 , 68, 427-32	5
1931	Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. 2010 , 68, 409-14	7
1930	Methodological aspects of lung cancer clinical trials in the era of targeted agents. 2010 , 67, 127-35	26
1929	First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. 2010 , 69, 218-24	11
1928	Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 2010 , 68, 319-31	50

1927	Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: a multi-center phase II study. 2010 , 69, 319-22	7
1926	Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies. 2010 , 69, 302-6	11
1925	The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. 2010 , 69, 323-9	50
1924	A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. 2010 , 70, 71-6	12
1923	Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. 2010 , 70, 200-4	5
1922	Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer. 2010 , 70, 168-73	9
1921	A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. 2010 , 70, 340-6	15
1920	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). 2010 , 70, 301-7	34
1919	Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. 2010 , 70, 233-46	14
1918	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. 2010 , 7, 401-14	205
1917	Pemetrexed in advanced non-small-cell lung cancer. 2010 , 11, 1387-402	34
1916	Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. 2010 , 11, 25	25
1915	Management of patients with advanced non-small cell lung cancer: current and emerging options. 2010 , 70, 167-79	17
1914	Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib. 2010 , 11, 57-60	6
1913	Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. 2010 , 11, 126-31	20
1912	Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. 2010 , 11, 192-7	11
1911	Second-line treatment for non-small-cell lung cancer: one size does not fit all. 2010 , 11, 320-7	10
1910	Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. 2010 , 11, 252-7	13

1909	Study of use of pemetrexed in non-small cell lung cancer. 2010 , 34, 194-203		
1908	Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). <i>Journal of Clinical Oncology</i> , 2010 , 28, 753-60	2.2	146
1907	Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. 2010 , 16, 2466-73		82
1906	Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method. 2010 , 49, 2925-31		44
1905	Survival comparison between glioblastoma multiforme and other incurable cancers. 2010 , 17, 417-21		112
1904	The role of the percutaneous biopsy in the evolving diagnosis and treatment of lung cancer. 2010 , 65, 951-2		7
1903	Parameters for individualizing systemic therapy in non-small cell lung cancer. 2010 , 13, 196-204		12
1902	ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. 2010 , 46, 1554-62		23
1901	Gefitinib for the treatment of non-small-cell lung cancer. 2010 , 11, 1343-57		19
1900	Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). 2010 , 69 Suppl 1, S1-3		1
1899	Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. 2010 , 69 Suppl 1, S4-10		13
1898	Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. 2010 , 69 Suppl 1, S11-7		24
1897	Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. 2010 , 69 Suppl 1, S18-23		10
1896	Results of surgical resection for patients with large cell carcinoma of the lung. 2010 , 8, 391-4		10
1895	Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer. 2010 , 109, 338-44		5
1894	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. 2010 , 11, 521-9		982
1893	The classification of lung carcinoma: time to change the morphology-based approach?. 2010 , 18, 161-72		19
1892	The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial. 2010 , 11, 321-4		5

1891	Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. 2010 , 29, 38		12
1890	Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy. 2010 , 29, 7		9
1889	Biological markers in lung cancer: A clinician's perspective. 2010 , 6, 123-35		38
1888	Advances in chemotherapy in advanced non-small-cell lung cancer. 2010 , 11, 2997-3007		26
1887	Valutazioni di farmacoeconomia che danno risultati opposti. 2010 , 3, 89-90		
1886	Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer?. 2010 , 11, 1605-9		4
1885	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry. 2010 , 53, 1306-18		54
1884	Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. 2011 , 15, 159-66		19
1883	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3307-15	2.2	343
1882	Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1067-74	2.2	234
1881	The BATTLE trial: personalizing therapy for lung cancer. 2011 , 1, 44-53		660
1880	Diagnostic workup of lung cancer. 2011 , 20, 667-79		3
1879	[What choice of first-line treatment?]. 2011 , 67 Suppl 1, S20-3		
1878	A decade of advances in treatment for advanced non-small cell lung cancer. 2011 , 32, 839-51		50
1877	Traitement d'induction et de maintenance des CBNPC au stade m̄tastatique. 2011 , 3, 365-371		
1876	La radio-chimioth̄rapie exclusive des cancers bronchiques non ^ petites cellules. 2011 , 3, 353-359		
1875	Current management of small cell lung cancer. 2011 , 32, 853-63		24
1874	[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)]. 2011 , 28, 51-7		6

1873	Pemetrexed in advanced non-small cell lung cancer. 2011 , 10, 311-7	13
1872	Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. 2011 , 11, 1223-31	25
1871	Cancer: beyond speciation. 2011 , 112, 283-350	52
1870	Pathology of lung cancer. 2011 , 32, 669-92	346
1869	Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. 2011 , 14, 41-52	83
1868	A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. 2011 , 14, 836-45	60
1867	Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. 2011 , 71, 191-8	41
1866	A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. 2011 , 71, 151-5	11
1865	Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. 2011 , 72, 327-32	22
1864	Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. 2011 , 71, 244; author reply 245	1
1863	Diverging prognostic impacts of hypoxic markers according to NSCLC histology. 2011 , 72, 294-302	35
1862	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. 2011 , 73, 338-44	4
1861	Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. 2011 , 74, 85-8	18
1860	Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. 2011 , 74, 69-74	17
1859	Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. 2011 , 74, 132-8	94
1858	Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. 2011 , 74, 30-4	22
1857	The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. 2011 , 72, 265-70	17
1856	Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. 2011 , 73, 1-10	21

1855	Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the LUng cancer maNagement) study. 2011 , 74, 462-8	11
1854	Fifth Educational Symposium of the Spanish Lung Cancer Group: report on the Molecular Biology Workshop. 2011 , 74, 535-43	1
1853	Predictive markers in the adjuvant therapy of non-small cell lung cancer. 2011 , 74, 355-63	21
1852	Tumours. 2011 , 531-705	
1851	Thymidylate synthase inhibitors for non-small cell lung cancer. 2011 , 20, 1343-56	24
1850	Role of genotyping in non-small cell lung cancer treatment: current status. 2011 , 71, 2231-46	17
1849	Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. 2011 , 365, 158-67	8
1848	Maintenance therapy in NSCLC: why? To whom? Which agent?. 2011 , 30, 50	19
1847	The BATTLE to personalize lung cancer prevention through reverse migration. 2011 , 4, 962-72	40
1846	[What is the best sequence of treatment for patients with EGFR mutations?]. 2011 , 67 Suppl 1, S24-9	1
1845	Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. 2011 , 49, 1591-603	41
1844	Induction Chemotherapy. 2011 ,	1
1843	[A brief overview of a lung cancer biomarker: thymidylate synthase]. 2011 , 28, 773-7	4
1842	The changing pathology of lung cancer. 2011 , 20, 637-53	10
1841	Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. 2011 , 304, 144-53	10
1840	Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. 2011 , 309, 228-35	37
1839	A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019). 2011 , 47, 1653-9	4
1838	Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication. 2011 , 47, 1603-5	11

1837	[Non-small cell lung carcinoma: Perspectives for the twenty-first century?]. 2011 , 40, 368-70	0
1836	2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy. 2011 , 47 Suppl 3, S248-57	5
1835	Second-line treatment options in advanced non-small cell lung cancer. 2011 , 47 Suppl 3, S258-71	1
1834	67 INVITED Stage III-N2 Non-Small Cell Lung Cancer [Choice of Chemotherapy Schemes. 2011 , 47, S18-S19	
1833	New driver mutations in non-small-cell lung cancer. 2011 , 12, 175-80	881
1832	A retrospective study of pemetrexed combined with oxaliplatin as second-line treatment for advanced non-small-cell lung cancer: Comparable toxicity, better outcome. 2011 , 2, 201-206	
1831	Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences. 2011 , 8, 5-16	
1830	Molecular tumor classification using a 92-gene assay in the differential diagnosis of squamous cell lung cancer. 2011 , 8, 123-131	
1829	Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. 2011 , 72, 333-9	37
1828	First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. 2011 , 22, 559-566	61
1827	First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer [A Review. 2011 , 3, 116-120	4
1826	Personalized therapy for non-small cell lung cancer: hype or clinical reality?. 2011 , 23, 30-5	2
1825	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. 2011 , 16, 1714-32	5
1824	Radiotherapy and Third Generation Concurrent Chemotherapy Agents. 2011 , 291-312	
1823	Drugs, Genomic Response Signatures, and Customized Cancer Therapy. 301-319	
1822	Systemic Therapy for Lung Cancer for the Radiation Oncologist. 2011 , 247-266	
1821	Pathology of Lung Cancer. 2011 , 53-62	
1820	Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma. 2011 , 2, 52-61	13

1819	Emerging treatment options in the management of non-small cell lung cancer. 2011 , 2, 11-28	3
1818	Advances in the prevention and treatment of lung cancer. 2011 , 41, 142-9	5
1817	Afatinib treatment in advanced non-small cell lung cancer. 2011 , 2, 47-57	3
1816	A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. 2011 , 2, 465-470	3
1815	Adjuvant chemotherapy for early stage non-small cell lung cancer. 2011 , 1, 45	5
1814	Novel Cytotoxic Agents in Combination with Radiation in the Management of Locally Advanced Non-Small Cell Lung Cancer: Focus on Pemetrexed and Nab-Paclitaxel [Abraxane]. 2011 , 765-771	1
1813	Dramatic response to pemetrexed in a patient with pneumonic-type mucinous bronchioloalveolar carcinoma. 2011 , 6, 397-8	5
1812	DNA-targeted drugs. 2011 , 52-65	
1811	Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. 2011 , 6, e26646	60
1810	Duodenal perforation in a patient with non-small cell lung cancer receiving Pemetrexed-Cisplatin combination. 2011 , 2011, 1-4	
1809	You just can't call it lung cancer anymore. 2011 , 6, 239-40	4
1808	Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer. 2011 , 6, 399-403	3
1807	Maintenance therapy in advanced non-small cell lung cancer: current status and future implications. 2011 , 6, 174-82	30
1806	Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. 2011 , 6, 790-5	16
1805	Actual and predicted survival time of patients with spinal metastases of lung cancer: evaluation of the robustness of the Tokuhashi score. 2011 , 36, 983-9	53
1804	Primary squamous cell carcinoma of lung in a 7-year-old boy: a case report. 2011 , 33, e307-9	3
1803	Synchronous double primary lung cancers with different response to pemetrexed. 2011 , 22, 473-6	
1802	Chemoradiation therapy in nonsmall cell lung cancer. 2011 , 23, 140-9	26

1801	Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. 2011 , 23, 150-7	5
1800	Predicting response to chemotherapy with early-stage lung cancer. 2011 , 17, 49-56	10
1799	Novel therapies for non-small cell lung cancer. 2011 , 26, 175-85	10
1798	Factors driving the choice of the best second-line treatment of advanced NSCLC. 2011 , 6, 44-51	14
1797	Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. 2011 , 6, 545-52	23
1796	Molecular predictors of response to chemotherapy in non-small cell lung cancer. 2011 , 17, 104-13	23
1795	Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. 2011 , 25, 921-8	66
1794	New discoveries in lung cancer biology: paving the road of personalized medicine. 2011 , 8, 1-4	
1793	What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. 2011 , 43, 103-15	46
1792	Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. 2011 , 6, 1190-9	71
1791	Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. 2011 , 140, 117-126	61
1790	Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatin. 2011 , 6, 1320-9	21
1789	An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. 2011 , 6, 1400-6	14
1788	A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. 2011 , 6, 358-64	19
1787	Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. 2011 , 6, 768-73	5
1786	A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. 2011 , 6, 1907-14	65
1785	Anticancer treatment for advanced non-small cell lung cancer. 2011 , 8, 124-133	2
1784	Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients. 2011 , 6, 1247-53	10

1783	Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. 2011 , 39, 1011-7	19
1782	Emerging treatments for small-cell lung cancer: Phase II and III trials. 2011 , 1, 255-263	
1781	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. 2011 , 6, 1474-80	131
1780	Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity. 2011 , 6, 641-2	5
1779	A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. 2011 , 6, 1379-91	79
1778	Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. 2011 , 6, 489-93	74
1777	Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). 2011 , 6, 1741-5	9
1776	Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. 2011 , 6, 2120-9	28
1775	Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. 2011 , 6, 1039-49	54
1774	[Recent progress for chemotherapy in advanced non-small cell lung cancer]. 2011 , 100, 763-71	
1773	Therapeutische Strategien bei SCLC und NSCLC. 2011 , 14, 24-34	
1772	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. 2011 , 2, 1059-1064	1
1771	Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. 2011 , 6, 1392-9	87
1770	Comparison of nedaplatin and irinotecan for patients with squamous and nonsquamous cell carcinoma of the lung: meta-analysis of four trials. 2011 , 6, 128-31	8
1769	A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. 2011 , 6, 55-63	21
1768	Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. 2011 , 6, 927-33	36
1767	Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. 2011 , 16, 1210-20	14
1766	Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. 2011 , 102, 1032-7	99

1765	Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer. 2011 , 7, 376-84	1
1764	Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. 2011 , 104, 1594-601	138
1763	An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. 2011 , 7 Suppl 2, 13-21	5
1762	Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. 2011 , 7 Suppl 2, 22-33	19
1761	Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. 2011 , 7 Suppl 2, 34-40	7
1760	Classification of lung cancer. 2011 , 46, 178-86	32
1759	Personalized treatment of lung cancer. 2011 , 38, 274-83	33
1758	Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. 2011 , 11, 93	15
1757	Lung cancer: New biological insights and recent therapeutic advances. 2011 , 61, 91-112	329
1756	Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. 2011 , 12, 360-8	22
1755	Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvuA11 (N1622097) trial. 2011 , 12, 407-11	38
1754	Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (EP1-017). 2011 , 12, 100-4	7
1753	Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective. 2011 , 12, 335-40	2
1752	Monoclonal antibodies against EGFR in non-small cell lung cancer. 2011 , 80, 1-9	34
1751	Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). 2012 , 81, 49-57	21
1750	Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. 2011 , 663, 17-26	49
1749	NSCLC: novel targeted therapies offer hope for the future. 2011 , 12, 6-9	
1748	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. 2011 , 5, 413-24	21

1747	Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?. 2011 , 66, 273-5	6
1746	Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. 2011 , 8, 235-241	
1745	Systemische Therapie des nichtkleinzelligen Lungenkarzinoms. 2011 , 25, 224-230	
1744	Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. 2011 , 17, 702-708	1
1743	Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. 2011 , 16, 287-93	78
1742	Clinical observation of pemetrexed on advanced non-small-cell lung cancer. 2011 , 10, 140-143	2
1741	Häoptysen nach Chemotherapie eines Adenokarzinoms der Lunge mit Pemetrexed. 2011 , 8, 268-272	0
1740	[Treatment of non-small cell lung cancer]. 2011 , 52, 1414-21	
1739	A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. 2011 , 67, 751-64	61
1738	Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. 2011 , 67, 791-7	5
1737	A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. 2011 , 68, 415-22	1
1736	Drug therapy of cancer. 2011 , 67, 437-47	18
1735	High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. 2011 , 28, 300-6	9
1734	Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases. 2011 , 28 Suppl 1, S570-6	2
1733	Monoclonal antibodies for medical oncology: a few critical perspectives. 2011 , 13, 84-7	5
1732	Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. 2011 , 13, 460-71	22
1731	Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?. 2011 , 4, 19-22	0
1730	Maintenance Therapy for NSCLC: Consensus and Controversy. 2011 , 23, 254-8	6

1729	How affordable are targeted therapies in non-small cell lung cancer?. 2011 , 12, 1-11	11
1728	Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. 2011 , 6, 17	8
1727	Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulations. 2011 , 30, 2601-21	167
1726	A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. 2011 , 117, 795-801	8
1725	Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. 2011 , 117, 3416-23	107
1724	Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. 2011 , 117, 3069-80	15
1723	Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer. 2011 , 79, 1395-401	27
1722	Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. 2011 , 12, 138-41	14
1721	Genomic and Cellular Pathology of Lung Cancer. 2011 , 7, 313-322	1
1720	An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer. 2011 , 7, 354-363	
1719	Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. 2011 , 71, 4955-67	81
1718	Treatment of advanced lung cancer in the elderly. 2011 , 39, 107-15	10
1717	Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. 2011 , 22, 2482-2488	11
1716	Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer. 2011 , 365, 1426-35	5
1715	Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. 2011 , 32, 22-31	128
1714	Systemische Behandlung nicht kleinzelliger und kleinzelliger Lungenkarzinome [Multimodale und molekulare Therapiekonzepte. 2011 , 40, 566-575	
1713	Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. 2011 , 32, 78-93	8
1712	Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients. 2011 , 18, 1640-50	1

1711	[Current treatment concepts of lung cancer]. 2011 , 136, 1901-6		0
1710	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. 2011 , 27, 2193-201		3
1709	Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer. 2011 ,		0
1708	Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1075-82	2.2	43
1707	Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. 2011 , 12, 112-8		33
1706	Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. 2011 , 35, 15-25		240
1705	The importance of ultrasound in staging and gaining a pathological diagnosis in patients with lung cancer--a two year single centre experience. 2011 , 66, 414-7		20
1704	New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease. 2011 , 17, 4192-9		15
1703	Customizing systemic therapy in patients with advanced non-small cell lung cancer. 2011 , 3, 207-18		8
1702	Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. 2011 , 3, 139-57		19
1701	Lung cancer in never smokers. 2011 , 7, 1195-211		30
1700	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. 2011 , 3, 113-25		77
1699	Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. 2011 , 16, 1307-15		21
1698	Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. 2011 , 20, 45-52		18
1697	Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1140-5	2.2	92
1696	Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer. 2011 , 18, 77-83		23
1695	Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. 2011 , 11, 1587-97		12
1694	Emerging antiangiogenic therapies for non-small-cell lung cancer. 2011 , 11, 1607-18		13

1693	Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. 2011 , 136, 228-38		33
1692	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3825-31	2.2	229
1691	Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer. 2011 , 57, 147-55		12
1690	Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancer. 2011 , 5, 177-84		21
1689	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. 2011 , 22, 1507-1519		98
1688	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 2011 , 6, 244-85		3178
1687	BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. 2011 , 6, 109-14		48
1686	Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer. 2011 , 34, 326-8		3
1685	Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. 2011 , 6, 786-9		14
1684	Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach. 2011 , 80, 350-8		9
1683	Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study. 2011 , 6, 156-60		7
1682	Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. 2011 , 6, 64-70		198
1681	Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. 2011 , 34, 249-53		57
1680	Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. 2011 , 6, 451-8		196
1679	Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3120-5	2.2	156
1678	Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2543-9	2.2	52
1677	Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). 2011 , 22, 2466-2470		147
1676	Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. 2011 , 11, 541-9		22

1675	Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. 2011 , 38, 239-43		48
1674	Afatinib (BIBW 2992) development in non-small-cell lung cancer. 2011 , 7, 817-25		50
1673	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. 2011 , 22, 2616-2624		279
1672	Evaluation of adjunct immunohistochemistry on reporting patterns of non-small cell lung carcinoma diagnosed histologically in a regional pathology centre. 2011 , 64, 1136-8		8
1671	Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer. 2011 , 3, 163-70		12
1670	Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. 2011 , 22, 1791-7		32
1669	An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). 2011 , 3, 3506-24		4
1668	Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2319-26	2.2	477
1667	Class III β -tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. 2011 , 17, 5205-14		33
1666	A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding. 2012 , 302, C1405-12		28
1665	Making a Difference with Teamwork. 2012 , 19, 5-6		78
1664	Optimizing patient outcome: of equal importance in the palliative setting. 2012 , 49, 255-9		2
1663	The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment. 2012 , 19, S16-23		35
1662	Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. 2012 , 23, 1223-1229		21
1661	Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. 2012 , 19, S52-8		96
1660	Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer. 2012 , 2012, 419402		2
1659	Going beyond EGFR. 2012 , 23 Suppl 10, x197-203		8
1658	MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. 2012 , 56, 645-54		48

1657	The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. 2012 , 19, S24-32	25
1656	Personalized choice of maintenance therapies in non-small-cell lung cancer. 2012 , 19, S64-72	2
1655	Precision medicine for lung cancer: role of the surgical pathologist. 2012 , 136, 1186-9	6
1654	Applications of MicroRNAs in the Diagnosis and Prognosis of Lung Cancer. 2012 , 6, 197-207	31
1653	Survival following surgery with or without adjuvant chemotherapy for stage I-IIIa non-small cell lung cancer: an east asian population-based study. 2012 , 17, 1294-302	10
1652	Ancillary testing in lung cancer diagnosis. 2012 , 2012, 249082	13
1651	EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. 2012 , 19, e67-74	13
1650	Non-small-cell lung carcinoma subtyping on cytology without the use of immunohistochemistry - can we meet the challenge?. 2012 , 56, 413-8	3
1649	Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report. 2012 , 2, 152	4
1648	Interobserver agreement in determining non-small cell lung cancer subtype in specimens acquired by EBUS-TBNA. 2012 , 40, 699-705	27
1647	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. 2012 , 18, 1472-82	865
1646	New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. 2012 , 18, 3002-7	28
1645	Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer. 2012 , 35, 115-9	15
1644	IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications. 2012 , 27, 340-53	48
1643	Immunohistochemical study of Napsin A and thyroid transcription factor-1 in non-small-cell lung carcinoma. 2012 , 32, 47-51	
1642	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii56-64	342
1641	Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact. 2012 , 137, 946-56	46
1640	Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. 2012 , 18, 6771-83	136

1639	Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. 2012 , 8, 57-62	3
1638	Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. 2012 , 17, 682-93	28
1637	Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. 2012 , 18, 1837-47	43
1636	Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. 2012 , 19, e9-e15	35
1635	Should we abandon standard forceps biopsy to diagnose an endobronchial lesion?. 2012 , 39, 513-4	
1634	Worldwide overview of the current status of lung cancer diagnosis and treatment. 2012 , 136, 1478-81	47
1633	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. 2012 , 185, 1316-22	196
1632	[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib]. 2012 , 66, 89-95	4
1631	[Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)]. 2012 , 66, 212-7	3
1630	Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. 2012 , 19, 3689-700	10
1629	Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. 2012 , 8, 1239-51	21
1628	Targeted therapies for advanced non-small cell lung cancer. 2012 , 15, 641-55	1
1627	Management of advanced lung cancer in resource-constrained settings: a perspective from India. 2012 , 12, 1479-95	29
1626	Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?. 2012 , 12, 529-39	5
1625	A phase II randomized study of cisplatin-pemetrexed plus either enzastaurin or placebo in chemo-naïve patients with advanced non-small cell lung cancer. 2012 , 82, 25-9	12
1624	Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). 2012 , 106, 658-65	14
1623	Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601). 2012 , 107, 1474-80	5
1622	A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. 2012 , 107, 604-11	15

1621	EC145: a novel targeted agent for adenocarcinoma of the lung. 2012 , 21, 755-61		32
1620	Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. 2012 , 23, 388-94		76
1619	Methodology for comparative effectiveness research: potential and limitations. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4185-7	2.2	31
1618	Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. 2012 , 11, 616-28		40
1617	Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. 2012 , 35, 18-25		30
1616	Interstitial pneumonitis after treatment with pemetrexed: a rare event?. 2012 , 58, 84-8		13
1615	Therapeutic advances in non-small cell lung cancer. 2012 , 67, 1097-101		20
1614	The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. 2012 , 23, 78-85		40
1613	The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer. 2012 , 6, 137-47		3
1612	Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer. 2012 , 6, 117-24		6
1611	A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. 2012 , 2012, 480961		19
1610	ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. 2012 , 7, 663-71		46
1609	Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?. 2012 , 23 Suppl 10, x189-92		11
1608	Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome. 2012 , 35, 783-6		8
1607	Lung Cancer and Other Pulmonary Neoplasms. 2012 , 1264-1272		3
1606	Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. 2012 , 7, 105-14		33
1605	FGFR1 amplification in squamous cell carcinoma of the lung. 2012 , 7, 1775-1780		147
1604	Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. 2012 , 7, 137-42		163

1603	Subclassification of non-small cell lung cancer by cytologic sampling: a logical approach with selective use of immunocytochemistry. 2012 , 56, 419-24	13
1602	Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer. 2012 , 35, 600-3	12
1601	Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors. 2012 , 6, 407-19	4
1600	First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. 2012 , 10, 847-56	23
1599	Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. 2012 , 4, 849-858	5
1598	Ask the Experts: Lung cancer management: leaving behind the 'one-fits-all' concept for a personalized approach. 2012 , 9, 367-372	
1597	Personalized medicine for lung cancer. 2012 , 1, 83-86	
1596	Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature. 2012 , 91, 179-194	43
1595	Making the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue. 2012 , 13, 1475-87	30
1594	Induktions- und Erhaltungstherapie beim fortgeschrittenen, nicht plattenepithelialen NSCLC. 2012 , 15, 50-51	
1593	Skin metastases in non-small cell lung cancer. 2012 , 344, 59-62	5
1592	Non small-cell lung cancer in a 15-year-old nonsmoker. 2012 , 7, e12-3	1
1591	Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. 2012 , 7, 766-7	7
1590	Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer. 2012 , 7, 982-92	13
1589	Demographic profile of lung cancer patients at the Universitas Academic Hospital Bronchoscopy Unit in Bloemfontein. 2012 , 27, 130-132	
1588	Personalized medicine in the treatment of advanced nonsmall cell lung cancer: step-by-step progress. 2012 , 24, 115-6	
1587	Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial. 2012 , 7, 1423-31	7
1586	A 66-year-old woman with newly diagnosed oligometastatic non-small cell lung cancer. 2012 , 10, 297-301	1

1585	S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type. 2012 , 3, 405-410	1
1584	Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients. 2012 , 7, 57-63	8
1583	Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada. 2012 , 7, 1155-63	24
1582	High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. 2012 , 7, 833-40	87
1581	Non-small cell lung cancer. 2012 , 10, 1236-71	270
1580	[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 3) Non-small cell lung cancer]. 2012 , 101, 2520-5	1
1579	A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. 2012 , 7, 196-202	24
1578	Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung. 2012 , 7, 1400-5	33
1577	Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. 2012 , 7, 1041-8	23
1576	Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer. 2012 , 4, 1010-1016	11
1575	Primary treatment of advanced non-small-cell lung cancer: role of monoclonal antibodies. 2012 , 1, 219-225	
1574	Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. 2012 , 7, 841-9	68
1573	Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO-cGMP signaling in lung adenocarcinoma cells in vitro and in vivo. 2012 , 41, 24-30	9
1572	Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. 2012 , 7, 579-86	60
1571	Genetic changes in squamous cell lung cancer: a review. 2012 , 7, 924-33	98
1570	Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. 2012 , 7, 1713-21	40
1569	The introduction of systematic genomic testing for patients with non-small-cell lung cancer. 2012 , 7, 1767-1774	80
1568	The surgeon's role in molecular biology. 2012 , 144, S18-22	6

1567	Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation. 2012 , 13, 685-97		3
1566	Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. 2012 , 61, 1017-25		79
1565	Clinical trial design in the age of molecular profiling. 2012 , 823, 19-34		2
1564	Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. 2012 , 13, e418-26		152
1563	Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4501-7	2.2	36
1562	Lung Cancer Therapy Annual 7. 2012 ,		0
1561	EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. 2012 , 8, 1015-29		15
1560	Utility of small biopsies for diagnosis of lung nodules: doing more with less. 2012 , 25 Suppl 1, S43-57		24
1559	Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. 2012 , 13, 247-55		459
1558	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. 2012 , 13, 528-38		777
1557	Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. 2012 , 23, 2088-2093		21
1556	Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. 2012 , 461, 629-38		27
1555	miRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes. 2012 , 138, 1641-50		54
1554	Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. 2012 , 25, 364-70		9
1553	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-8		4
1552	Lung cancer: multidisciplinary approach to tissue sampling. 2012 , 50, 951-60		2
1551	Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study. 2012 , 105, 161-6		14
1550	Antibioprophylaxie et facteurs de croissance mđullaire dans la prise en charge du cancer bronchique. 2012 , 4, 530-536		

1549	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-268		
1548	Saudi Lung Cancer Guidelines Supplement 2012. Introduction from the Guest Editor. 2012 , 5 Suppl 1, S2-3		
1547	Vandetanib for the treatment of lung cancer. 2012 , 21, 1211-21		5
1546	Disparities in subgroup populations enrolled in lung cancer trials. 2012 , 6, 163-72		
1545	Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. 2012 , 186, 1160-7		36
1544	Exhaled breath volatile organic compound biomarkers in lung cancer. 2012 , 6, 027106		41
1543	Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTION observational study. 2012 , 28, 1253-62		8
1542	Sorafenib in non-small cell lung cancer. 2012 , 21, 1417-26		20
1541	Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. 2012 , 106, 473-92		8
1540	Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2055-62	2.2	533
1539	Why RECIST works and why it should stay--counterpoint. 2012 , 72, 5151-7; discussion 5158		20
1538	Problems involved in the clinical trials for non-small cell lung carcinoma. 2012 , 38, 194-202		6
1537	Systemic issues in small cell lung cancer. 2012 , 36, 131-55		3
1536	A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. 2012 , 48, 564-70		27
1535	ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. 2012 , 48, 961-73		71
1534	Crizotinib in the treatment of non-small-cell lung cancer. 2012 , 13, 1195-201		60
1533	Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. 2012 , 77, 331-8		47
1532	The antifolates. 2012 , 26, 629-48, ix		147

1531	Expression of Bim, Noxa, and Puma in non-small cell lung cancer. 2012 , 12, 286	10
1530	Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study. 2012 , 12, 296	9
1529	Treatment of lung cancer. 2012 , 50, 961-74	62
1528	Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. 2012 , 13, 1073-86	26
1527	Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. 2012 , 30, 17-34	26
1526	Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. 2012 , 13, 340-6	28
1525	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. 2012 , 13, 391-5	114
1524	Recurrent non-small-cell lung cancer in elderly patients: a case-based review of current clinical practice. 2012 , 9, 165-170	
1523	EGFR inhibition and other targeted therapies in NSCLC. 2012 , 9, S30-S34	
1522	Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. 2012 , 84, 47-58	32
1521	Squamous-cell carcinoma of the lungs: is it really so different?. 2012 , 84, 327-39	11
1520	Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges. 2012 , 38, 861-7	18
1519	Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. 2012 , 38, 807-14	17
1518	Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. 2012 , 15, 65-71	26
1517	Lung cancer associated venous thromboembolic disease: a comprehensive review. 2012 , 75, 1-8	34
1516	Cytology-based treatment decision in primary lung cancer: is it accurate enough?. 2012 , 75, 293-9	15
1515	Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. 2012 , 76, 78-83	26
1514	Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. 2012 , 75, 269-74	8

1513	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. 2012 , 76, 1-18	171
1512	Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. 2012 , 76, 222-7	31
1511	Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer. 2012 , 76, 491-2	5
1510	Retrospective study of erlotinib in patients with advanced squamous lung cancer. 2012 , 77, 128-33	28
1509	Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. 2012 , 77, 376-82	44
1508	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. 2012 , 77, 346-52	22
1507	Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. 2012 , 77, 339-45	27
1506	Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. 2012 , 77, 389-93	17
1505	Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?. 2012 , 77, 365-70	96
1504	Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. 2012 , 77, 475-81	10
1503	Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. 2012 , 78, 92-9	32
1502	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). 2012 , 78, 239-44	26
1501	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. 2012 , 7, 199-210	25
1500	Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1. 2012 , 24, 226-31	9
1499	Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?. 2012 , 13, 478-90	3
1498	Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a brazilian center experience. 2012 , 12, 207-16	4
1497	Lungenkrebs: Operation, Strahlentherapie und systemische Therapie. 2012 , 7, 133-139	
1496	Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials. 2012 , 70, 861-73	8

1495	Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. 2012 , 70, 883-90	20
1494	A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer. 2012 , 70, 531-7	14
1493	Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. 2012 , 70, 271-6	11
1492	Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide. 2012 , 1, 39-44	3
1491	Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. 2012 , 107, 1107-15	47
1490	Classification of the four main types of lung cancer using a microRNA-based diagnostic assay. 2012 , 14, 510-7	82
1489	Molecular Pathology of Lung Cancer. 2012 ,	5
1488	Molecular Basis for the Current Lung Cancer Classification. 2012 , 75-85	
1487	Personalizing lung cancer prevention through a reverse migration strategy. 2013 , 329, 221-40	4
1486	Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy. 2012 , 7, e48350	27
1485	Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System. 2012 , 2, 77-92	2
1484	The Role of Histology and Molecular Markers in NSCLE. 2012 , 27, 38-40	
1483	Foot pain: uncommon presentation of lung cancer. 2012 , 2012,	4
1482	The place of TKI in the treatment of EGFR mutation-positive lung cancer. 2012 , 2,	
1481	Adjuvant treatment of older patients with lung cancer. 2012 , 315-9	
1480	A Minimal Immunohistochemical Panel for Subtyping Poorly Differentiated Non-Small Cell Lung Carcinoma: A Tissue Microarray Study Simulating Small Biopsy Conditions. 2012 , 11, 21	2
1479	PharmaForum. 2012 , 35, 528-529	
1478	PharmaForum. 2012 , 35, 390-391	

1477	Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients. 2012 , 7,	1
1476	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. 2012 , 2012, 837306	22
1475	Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis. 2012 , 3, 43-51	2
1474	The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3012-9	2.2 125
1473	Combined double CK5/P63 stain: useful adjunct test for diagnosing pulmonary squamous cell carcinoma. 2012 , 40, 943-8	12
1472	The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma. 2012 , 40, 949-55	19
1471	Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. 2012 , 131, E822-9	98
1470	Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. 2012 , 118, 2525-31	35
1469	Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. 2012 , 118, 4502-11	202
1468	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. 2012 , 118, 4694-705	34
1467	Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. 2012 , 118, 5580-7	21
1466	Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. 2012 , 118, 5588-94	42
1465	Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. 2012 , 118, 6234-42	72
1464	Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. 2012 , 120, 185-95	78
1463	Driver mutations as predictive biomarkers in lung cancer. 2012 , 1, 21-29	
1462	Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). 2012 , 30, 1802-11	9
1461	Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer. 2012 , 43, 215-23	11
1460	Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients. 2012 , 29, 640-3	2

1459	Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. 2012 , 138, 545-54	6
1458	Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. 2012 , 138, 745-51	11
1457	Le coǔ du traitement des cancers bronchopulmonaires non ^petites cellules (CBNAPC). 2012 , 14, 310-315	
1456	Factors associated with long-term survival of patients with advanced non-small cell lung cancer. 2012 , 17, 134-42	36
1455	Pulmonary adenocarcinoma: a renewed entity in 2011. 2012 , 17, 50-65	56
1454	Personalized medicine for lung cancer: new challenges for pathology. 2012 , 60, 531-46	73
1453	Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. 2012 , 13, 24-30	27
1452	Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. 2012 , 13, 239-51	24
1451	Pemetrexed-induced lung toxicity: a case report. 2012 , 24, 76-7	4
1450	Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. 2012 , 82, 200-12	9
1449	Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions. 2012 , 82, 338-60	7
1448	Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. 2012 , 83, 130-44	22
1447	Prognostic impact of cell type under the seventh TNM staging system in resected non-small cell lung cancer. 2012 , 3, 249-254	
1446	Management of lung cancer. 2012 , 40, 202-207	
1445	Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer. 2012 , 103, 1065-70	16
1444	Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life. 2012 , 12, 14	9
1443	Acute small bowel obstruction: a rare initial presentation for the metastasis of the large-cell carcinoma of the lung. 2012 , 10, 26	11
1442	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. 2012 , 118, 164-72	29

1441	Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. 2012 , 118, 1607-18	21
1440	Effect of Feitai Capsule () on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer. 2012 , 18, 106-11	2
1439	A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. 2012 , 69, 709-22	9
1438	Erstlinientherapie beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom. 2012 , 9, 22-27	
1437	Das fortgeschrittene Lungenkarzinom. 2012 , 9, 49-54	
1436	Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. 2012 , 138, 285-91	1
1435	Pemertrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer: a case report and literature review. 2012 , 11, 49-51	
1434	Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. 2013 , 52, 183-94	26
1433	Ancillary techniques on direct-smear aspirate slides: a significant evolution for cytopathology techniques. 2013 , 121, 120-8	97
1432	Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells. 2013 , 386, 1047-59	9
1431	The impact of genomic changes on treatment of lung cancer. 2013 , 188, 770-5	76
1430	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. 2013 , 9, 991-1003	6
1429	Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. 2013 , 13, 354	35
1428	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. 2013 , CD009256	44
1427	Histology as a potential clinical predictor of outcome in advanced non-small-cell lung cancer treated with vinorelbine and mitomycin combination chemotherapy. 2013 , 191, 271-80	3
1426	Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. 2013 , 15, 503-8	22
1425	Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. 2013 , 31, 927-36	10
1424	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. 2013 , 31, 1275-82	28

1423	Management of non-small-cell lung cancer: recent developments. 2013 , 382, 709-19	563
1422	Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. 2013 , 8, 107-16	7
1421	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. 2013 , 71, 705-11	6
1420	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. 2013 , 71, 307-19	14
1419	The efficacy and safety of standardized allergen-removed Rhus verniciflua extract as maintenance therapy after first-line chemotherapy in patients with advanced non-small cell lung cancer. 2013 , 41, 773-87	19
1418	Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents. 2013 , 73, 517-32	5
1417	First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. 2013 , 73, 357-69	12
1416	Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. 2013 , 119, 2754-64	91
1415	'Who', 'when' and 'how' in re-irradiation of recurrent painful bone metastases. 2013 , 2, 33-7	1
1414	Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. 2013 , 82, 121-7	10
1413	A 75-year-old man with progressive bronchioalveolar carcinoma. 2013 , 40, e1-8	0
1412	Biologic approaches to drug selection and targeted therapy: hype or clinical reality?. 2013 , 23, 421-8	3
1411	Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer. 2013 , 67, 763-9	3
1410	Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. 2013 , 49, 2877-83	25
1409	Cáncer de pulmón no microcítico. 2013 , 11, 1429-1440	
1408	Pemetrexed in head and neck cancer: a systematic review. 2013 , 49, 492-501	10
1407	Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. 2013 , 35, 54-65	22
1406	Adjuvant treatment in resected non-small cell lung cancer: current and future issues. 2013 , 88, 375-86	9

1405	Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. 2013 , 82, 288-93		28
1404	Pemetrexed for the treatment of non-small cell lung cancer. 2013 , 14, 1545-58		21
1403	Crizotinib in the treatment of non--small-cell lung cancer. 2013 , 14, 473-80		32
1402	Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. 2013 , 24, 2390-6		56
1401	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. 2013 , 15, 977-84		17
1400	Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCCG0703. 2013 , 51, 28-34		9
1399	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. 2013 , 81, 377-381		7
1398	Lung Cancer Imaging. 2013 ,		1
1397	Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. 2013 , 14, 609-26		14
1396	Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. 2013 , 14, 627-35		9
1395	PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4349-57	2.2	268
1394	PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2895-902	2.2	453
1393	Maintenance therapy for advanced lung cancer: who, what, and when?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2983-90	2.2	12
1392	Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). <i>Journal of Clinical Oncology</i> , 2013 , 31, 3004-11	2.2	243
1391	A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. 2013 , 14, 215-23		37
1390	Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. 2013 , 11, 163		5
1389	Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. 2013 , 31, 1587-91		10
1388	[The relevance of biomarkers for personalised medicine]. 2013 , 56, 1480-8		1

1387	Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study. 2013 , 13, 474		13
1386	Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients. 2013 , 14, 139		15
1385	Leukocytes and systemic inflammatory response syndrome as prognostic factors in pulmonary embolism patients. 2013 , 13, 74		33
1384	Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials. 2013 , 18, 1005-13		3
1383	Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer. 2013 , 18, 988-96		3
1382	PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. 2013 , 36, 449-57		22
1381	Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung. 2013 , 14, 568-79		5
1380	Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. 2013 , 119, 2048-60		15
1379	Regionale Therapie maligner Tumoren. 2013 ,		
1378	Biomarkers in Oncology. 2013 ,		1
1377	Lung cancer: Maintenance therapy and precision medicine in NSCLC. 2013 , 10, 549-50		41
1376	An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. 2013 , 9, 1037-51		9
1375	Differential immunohistochemical localization of desmosomal plaque-related proteins in non-small-cell lung cancer. 2013 , 63, 103-13		26
1374	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1070-80	2.2	362
1373	Analisi critica di un campione di farmaci oncologici valutati dalla Commissione Tecnica Regionale della Regione Veneto. 2013 , 6, 1-10		
1372	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3327-34	2.2	2262
1371	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3342-50	2.2	222
1370	Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. 2013 , 49, 1216-25		79

1369	Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005. 2013 , 31, 167-74		2
1368	Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. 2013 , 137, 32-40		43
1367	Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. 2013 , 24, 59-66		82
1366	New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. <i>Journal of Clinical Oncology</i> , 2013 , 31, 992-1001	2.2	365
1365	New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1029-38	2.2	61
1364	Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis. 2013 , 18, 131-139		12
1363	Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas. 2013 , 25, 209-18		5
1362	Cost-effectiveness of gene-expression profiling for tumor-site origin. 2013 , 16, 46-56		2
1361	The evolution of tumor classification: a role for genomics?. 2013 , 24, 693-4		5
1360	Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma. 2013 , 14, 238-44		6
1359	Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study. 2013 , 31, 180-6		4
1358	Prospective observational comparison of clinical outcomes between african-american and caucasian patients receiving second-line treatment with pemetrexed for advanced non-small-cell lung cancer. 2013 , 14, 726-35		4
1357	Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. 2013 , 15, 485-97		11
1356	Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. 2013 , 81, 47-52		12
1355	Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer. 2013 , 80, 30-4		54
1354	A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ROS1 gene rearrangements. 2013 , 14, 592-5		25
1353	A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. 2013 , 81, 445-450		48
1352	Traitement des CBNPC au stade m̄tastatique. Acquis et bonnes pratiques. 2013 , 5, 427-435		

1351	Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. 2013 , 82, 511	1
1350	Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. 2013 , 79, 143-50	23
1349	Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer--a report of two cases. 2013 , 80, 111-3	6
1348	The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. 2013 , 81, 231-5	14
1347	Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. 2013 , 80, 326-32	23
1346	Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. 2013 , 82, 330-9	35
1345	Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. 2013 , 14, 164-71	8
1344	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. 2013 , 81, 97-101	34
1343	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. 2013 , 30, 298-312	10
1342	Suitability of computed tomography-guided biopsy specimens for subtyping and genotyping of non-small-cell lung cancer. 2013 , 14, 719-25	18
1341	Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. 2013 , 80, 185-90	24
1340	Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. 2013 , 14, 351-5	6
1339	Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. 2013 , 81, 428-434	9
1338	Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. 2013 , 49, 1058-64	48
1337	Other signalization targets. 2013 , 8, 69-77	5
1336	Personalized therapy on the horizon for squamous cell carcinoma of the lung. 2013 , 80, 249-55	46
1335	Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. 2013 , 24, 309-314	14
1334	Surgery for NSCLC in the era of personalized medicine. 2013 , 10, 235-44	75

1333	Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. 2013 , 81, 102-8	37
1332	Chemotherapy and Biological Agents. 2013 , 49-64	
1331	The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancer. 2013 , 49, 2269-70	1
1330	Identification of driver mutations in lung cancer: first step in personalized cancer. 2013 , 8, 3-14	20
1329	Axitinib for the treatment of advanced non-small-cell lung cancer. 2013 , 22, 765-73	7
1328	Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology. 2013 , Chapter 14, Unit 14.26	15
1327	Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. 2013 , 112, 461-6	44
1326	Erlotinib in the first-line treatment of non-small-cell lung cancer. 2013 , 13, 523-33	15
1325	Targeted therapy for non-small-cell lung cancer: past, present and future. 2013 , 13, 745-58	68
1324	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. 2013 , 72, 13-33	74
1323	Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. 2013 , 47, 189-97	40
1322	Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. 2013 , 39, 27-43	10
1321	Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. 2013 , 17, 85-90	62
1320	Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer. 2013 , 14, 62-9	16
1319	Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer. 2013 , 14, 50-4	12
1318	Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). 2013 , 14, 34-9	17
1317	Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases. 2013 , 14, 6-13	25
1316	Clinical factors predictive of long-term survival in advanced non-small cell lung cancer. 2013 , 79, 73-6	19

1315	Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. 2013 , 79, 20-6	37
1314	Clinical impact of ki-67 labeling index in non-small cell lung cancer. 2013 , 79, 1-7	64
1313	Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. 2013 , 13, 289-96	15
1312	Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. 2013 , 20, 5	15
1311	KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. 2013 , 20, 1381-8	63
1310	Brèves de L'ÆRIO. 2013 , 15, 61-64	
1309	Aflibercept in lung cancer. 2013 , 13, 115-20	6
1308	Defining risks of taxane neuropathy: insights from randomized clinical trials. 2013 , 19, 4570-7	40
1307	Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice. 2013 , 84, 255-64	9
1306	Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation. 2013 , 59, 414-9	7
1305	Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten. 2013 , 19, 821-834	
1304	Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial. 2013 , 31, 1330-8	10
1303	Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. 2013 , 62, 529-39	19
1302	Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). 2013 , 8, 1409-16	20
1301	An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. 2013 , 8, 1529-37	31
1300	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. 2013 , 19, 818-832	23
1299	Associations between TS, TTF-1, FR- β , FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. 2013 , 8, 1255-64	33
1298	The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. 2013 , 19, 2629-36	73

1297	Advances in personalized therapy for lung cancer. 2013 , 7, 475-85	8
1296	Modeling hard clinical end-point data in economic analyses. 2013 , 16, 1327-43	5
1295	Afatinib in advanced non-small-cell lung cancer. 2013 , 2, 493-504	
1294	Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. 2013 , 26, 239-46	12
1293	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. 2013 , 9, 327-45	8
1292	Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. 2013 , 26, 511-22	81
1291	Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. 2013 , 12, 2248-60	32
1290	Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytidine). 2013 , 3, 188	23
1289	Bevacizumab treatment for advanced non-small cell lung cancer: A case report. 2013 , 6, 1779-1783	2
1288	Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer. 2013 , 50, 122-7	12
1287	Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 2013 , 137, 668-84	287
1286	Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. 2013 , 137, 1274-81	46
1285	The current state of pemetrexed in ovarian cancer. 2013 , 22, 1201-10	2
1284	Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience. 2013 , 19, 202-7	2
1283	Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung. 2013 , 18, 1258-61	
1282	Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. 2013 , 21, 326-36	27
1281	Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. 2013 , 30, 191-8	54
1280	Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. 2013 , 24, 980-5	20

1279	Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. 2013 , 3, 261	57
1278	Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. 2013 , 20, e150-60	25
1277	Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). 2013 , 24, 1534-42	15
1276	The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. 2013 , 25, 121-9	9
1275	Histologic and molecular characterization of lung cancer with tissue obtained by electromagnetic navigation bronchoscopy. 2013 , 20, 10-5	15
1274	First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma: data on safety and efficacy. 2013 , 24, 736-42	6
1273	Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer. 2013 , 19, 222-30	9
1272	Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. 2013 , 36, 450-4	7
1271	Personalized Treatment of Lung Adenocarcinoma. 2013 , 20, 309-314	
1270	The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma. 2013 , 45, 553-8	31
1269	Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. 2013 , 36, 510-8	63
1268	Reply to F. Gelsomino et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3293-4	2.2 1
1267	Second-Line Therapy for Advanced NSCLC. 2013 , 18, 947-53	30
1266	Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung. 2013 , 21, 476-82	16
1265	Lack of improvement in overall survival with gemcitabine/ erlotinib maintenance and its relationship with pemetrexed use in the second-line setting. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1250-1252	4
1264	The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. 2013 , 18, 115-22	54
1263	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. 2013 , 24, 986-92	52
1262	Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. 2013 , 24, 1326-31	51

1261	Short hydration in chemotherapy containing cisplatin (75 mg/m ²) for patients with lung cancer: a prospective study. 2013 , 43, 1105-9		36
1260	Current therapeutic strategies and novel approaches in osteosarcoma. 2013 , 5, 591-616		154
1259	Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1009-20	2.2	104
1258	Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1990-6	2.2	23
1257	Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3303-6	2.2	51
1256	Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. 2013 , 59, 42-50		7
1255	Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. 2013 , 59, 307-13		8
1254	Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small cell lung cancer. 2013 , 36, 105-9		1
1253	Is immunohistochemistry always required to diagnose lung cancer?. 2013 , 20, 327-33		10
1252	Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. 2013 , 19, 200-7		130
1251	Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. 2013 , 2013, 964743		16
1250	Retrospective analysis of the clinical and demographic variables on the outcomes after second-line treatment in advanced non-small cell lung cancer. 2013 , 34, 274-9		2
1249	Histo-cytological diagnostic accuracy in lung cancer. 2014 , 25, 404-11		3
1248	Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC. 2013 , 2013, 436409		6
1247	Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?. 2013 , 2013, 905091		47
1246	Novel medium-term carcinogenesis model for lung squamous cell carcinoma induced by N-nitroso-tris-chloroethylurea in mice. 2013 , 104, 1560-6		10
1245	A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: further analysis of a thalidomide trial. 2013 , 2, 360-6		8
1244	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial. 2013 , 9, 331-41		1

1243	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. 2014 , 229, 97-9		83
1242	Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective. 2013 , 13, 1193-206		2
1241	Evidence-based role of bevacizumab in non-small cell lung cancer. 2013 , 24, 6-9		18
1240	Model Pharmacoeconomic Study on Iressa [®] (Gefitinib) as a First Line Treatment of Non-Small Cell Lung Cancer at Stage IIIB/IV in EGFR Mutation Positive Bulgarian Patients. 2013 , 27, 3586-3594		
1239	The place of pemetrexed in the management of non-small-cell lung cancer patients. 2013 , 13, 257-66		8
1238	Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3957-63	2.2	77
1237	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. 2013 , 19, 3068-77		192
1236	Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification. 2013 , 66, 832-8		13
1235	Estado actual del tratamiento del c�ncer pulmonar. 2013 , 24, 611-625		
1234	Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality". 2013 , 2, e78		15
1233	Efficacy of third-generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 Chinese patients with advanced non-small-cell lung cancer. 2013 , 4, 117-122		2
1232	Phase Ib safety and pharmacokinetic study of volociximab, an anti-�5� integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. 2013 , 24, 90-6		51
1231	Cancer survival extension from drug treatments. 2013 , 18, 467-485		
1230	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. 2013 , 14, 469-75		75
1229	Analysis of risk factors for severe adverse events of chemotherapy with pemetrexed and comparison of adverse event occurrence according to renal function. 2013 , 133, 1209-13		5
1228	Polymorphisms in thymidylate synthase and reduced folate carrier () genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. 2013 , 5, 1165-1170		27
1227	Chemotherapy: still an essential player in non-small-cell lung cancer treatment?. 2013 , 2, 381-390		
1226	Chemotherapy of advanced non-small-cell lung cancer: current landscape. 2013 , 3, 265-279		

1225	Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. 2013 , 8, 906-14	8
1224	Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. 2013 , 8, 1136-41	35
1223	Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. 2013 , 8, 1308-16	21
1222	Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. 2013 , 8, 892-8	30
1221	Analysis of Subgroup Data of Clinical Trials. 2013 , 1, 193-207	1
1220	A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. 2013 , 11, 389-94	12
1219	Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2013 , 143, e341S-e368S	138
1218	Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. 2013 , 42, 1088-92	3
1217	Impact of the new EGF receptor and ALK testing guideline on personalized lung cancer medicine. 2013 , 10, 415-417	
1216	Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. 2013 , 8, 19-30	69
1215	Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2013 , 143, e1S-e29S	418
1214	Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2013 , 143, e142S-e165S	618
1213	Targeting angiogenesis in non-small-cell lung cancer: a focus on current approaches and future developments. 2013 , 10, 503-517	
1212	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. 2013 , 8, 456-62	51
1211	Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer. 2013 , 143, 1626-1634	44
1210	Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy. 2013 , 2, 281-293	
1209	Conference Scene: Australia Lung Cancer Conference 2012: focus on systemic treatment of advanced non-small-cell lung cancer. 2013 , 2, 27-30	1
1208	Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. 2013 , 258, 1079-86	141

1207	Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. 2013 , 8, 930-9	49
1206	Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis. 2013 , 8, e74284	26
1205	Thymidylate synthase inhibitors for thoracic tumors. 2013 , 24, 57-67	0
1204	Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. 2013 , 8, 582-6	26
1203	Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy. 2013 , 1, 692-698	10
1202	Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. 2013 , 8, 1084-90	79
1201	Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. 2013 , 8, 753-8	33
1200	Genomewide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas. 2013 , 8, 562-73	20
1199	Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer. 2013 , 5, 15-20	3
1198	Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. 2013 , 5, 77-84	11
1197	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. 2013 , 4, 736-54	65
1196	Can microRNAs improve the management of lung cancer patients? A clinician's perspective. 2013 , 3, 953-63	17
1195	Biopsy and mutation detection strategies in non-small cell lung cancer. 2013 , 75, 181-7	10
1194	Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases. 2013 , 4, 55-59	0
1193	Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy. 2013 , 4, 9-14	5
1192	Role of the extracellular matrix in variations of invasive pathways in lung cancers. 2013 , 46, 21-31	6
1191	A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. 2013 , 8, e55917	39
1190	Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples. 2013 , 8, e56333	17

1189	Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. 2013 , 6, 803-9	2
1188	Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. 2013 , 54, 854-64	9
1187	Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant. 2013 , 1, 41-46	4
1186	Conventional Cancer Treatment. 2013 ,	6
1185	Squamous cell carcinoma of the lung. 1093-1113	
1184	Cytotoxic Chemotherapy for Non-small Cell Lung Cancer. 2014 , 34, 31	2
1183	Identifying differentially expressed genes and pathways in two types of non-small cell lung cancer: adenocarcinoma and squamous cell carcinoma. 2014 , 13, 95-102	27
1182	Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemo-naïve patients with EGFR-mutant lung adenocarcinoma. 2014 , 7, 799-805	12
1181	Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. 2014 , 7, 1185-93	14
1180	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. 2014 , 9, e85245	97
1179	Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. 2014 , 9, e103305	78
1178	Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules. 2014 , 7, 937-45	6
1177	Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. 2014 , 4, 386-401	12
1176	Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer. 2014 , 5, 103-13	20
1175	Survival and prognostic factors in patients with non-small cell lung cancer treated in private health care. 2014 , 17, 1001-14	14
1174	Erlotinib in the treatment of advanced squamous cell NSCLC. 2013 , 60, 676-82	2
1173	Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. 2014 , 21, e691-703	25
1172	Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. 2014 , 61, 233-40	22

1171	The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer. 2014 , 33, 105-14	6
1170	Molecular Targeted Therapy in Lung Cancer. 2014 , 34, 37	1
1169	Chemotherapy for lung cancers: here to stay. 2014 , e375-80	3
1168	50 Years of progress in the systemic therapy of non-small cell lung cancer. 2014 , 177-89	75
1167	MicroRNAs: a new key in lung cancer. 2014 , 74, 1105-11	58
1166	Development in the diagnostic lung cancer pathway: implication for treatment. 2014 , 3, 417-428	1
1165	Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL. 2014 , 31, 244	1
1164	Tumor acquisition for biomarker research in lung cancer. 2014 , 32, 291-8	3
1163	Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. 2014 , 2, 9	12
1162	Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer. 2014 , 74, 681-90	11
1161	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNAActive [®]) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. 2014 , 14, 748	74
1160	The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. 2014 , 60, 107-111	3
1159	Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study. 2014 , 14, 940	7
1158	Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer. 2014 , 15, 1542-51	14
1157	Safety and efficacy evaluation of albumin-bound paclitaxel. 2014 , 13, 511-20	25
1156	A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. 2014 , 110, 602-8	24
1155	Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. 2014 , 10, 2081-96	13
1154	Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. 2014 , 5, e1316	52

1153	A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer. 2014 , 15, 832-9	21
1152	Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma. 2014 , 7, 227-232	12
1151	Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. 2014 , 4, 157	37
1150	Promising targets and current clinical trials in metastatic squamous cell lung cancer. 2014 , 4, 320	5
1149	Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. 2014 , 138, 626-35	33
1148	The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. 2014 , 120, 3853-8	8
1147	Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer. 2014 , 8, 2453-2457	10
1146	Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue. 2014 , 4, 251	8
1145	Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. 2014 , 4, 258	2
1144	Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer. 2014 , 4, 190	39
1143	Prognosis of recurrent non-small cell lung cancer following complete resection. 2014 , 7, 1300-1304	27
1142	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. 2014 , 7, 1423-37	37
1141	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. 2014 , 4, 204	111
1140	Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2014 , 10, 931-8	18
1139	Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer. 2014 , 5, 525-9	1
1138	Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer. 2014 , 14, 365-76	7
1137	Updating the 2011 International Association for the Study of Lung Cancer classification of lung adenocarcinoma: main priorities and implications for clinicians. 2014 , 3, 149-158	
1136	Immunotherapy and lung cancer: current developments and novel targeted therapies. 2014 , 6, 1221-35	41

1135	Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging. 2014 , 19, 448-60	5
1134	Subtyping of nonsmall cell lung cancer on cytology specimens: reproducibility of cytopathologic diagnoses on sparse material. 2014 , 42, 105-10	3
1133	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. 2014 , 25, 1475-84	174
1132	Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. 2014 , 25, 1044-52	117
1131	First-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014 , 371, 2167-77	2116
1130	Câncer de pulmão. 2014 , 11, 3983-3994	
1129	A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. 2014 , 799, 85-117	76
1128	Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. 2014 , 10 Suppl 2, 2-10	3
1127	A prospective study of shortened vitamin supplementation prior to cisplatin-pemetrexed therapy for non-small cell lung cancer. 2014 , 19, 1194-9	14
1126	Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. 2014 , 41 Suppl 6, S35-41	68
1125	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2014 , 25 Suppl 3, iii27-39	521
1124	Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer. 2014 , 44, 472-8	3
1123	Advances in the diagnosis and treatment of non-small cell lung cancer. 2014 , 13, 557-64	15
1122	Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. 2014 , 140, 2047-57	24
1121	Frâie palliative Intervention. 2014 , 20, 998-1002	1
1120	Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed. 2014 , 36, 1141-3	1
1119	Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?. 2014 , 25, 1283-1293	14
1118	A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung. 2014 , 14, 684	10

1117	Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. 2014 , 14, 786	25
1116	Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. 2014 , 12, 343	9
1115	Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma. 2014 , 9, 103	4
1114	Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study. 2014 , 9, 991-997	41
1113	New developments in the treatment of squamous cell lung cancer. 2014 , 26, 152-8	16
1112	Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer. 2014 , 9, 222-30	10
1111	NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. 2014 , 9, 1146-53	6
1110	Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile. 2014 , 25, 368-74	1
1109	The clinical relevance of pathologic subtypes in metastatic lung adenocarcinoma. 2014 , 9, 654-63	18
1108	Vaccination therapy for non-small-cell lung cancer. 2014 , 26, 165-70	31
1107	Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. 2014 , 9, 18-25	55
1106	Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. 2014 , 9, 1354-62	31
1105	Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. 2014 , 9, 519-26	20
1104	Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. 2014 , 9, 59-64	162
1103	ALK inhibitors and advanced non-small cell lung cancer (review). 2014 , 45, 499-508	30
1102	Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. 2014 , 6, 4-15	17
1101	A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. 2014 , 65, 868-78	22
1100	Convex probe endobronchial ultrasound. 2014 , 35, 636-44	5

1099	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. 2014 , 25, 1681-1690	208
1098	Recurrent and Metastatic Non-Small-Cell Lung Cancer and Novel Targets. 2014 , 500-502	
1097	Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. 2014 , 311, 1975-6	20
1096	Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response. 2014 , 2014, 731925	4
1095	Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer. 2014 , 14, 207-14	16
1094	Chemotherapy in Metastatic NSCLC - New Regimens (Pemetrexed, Nab-Paclitaxel). 2014 , 4, 177	5
1093	Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer. 2014 , 2, 953-959	7
1092	The dose and risk factors for radiation exposure to medical staff during endobronchial ultrasonography with a guide sheath for peripheral pulmonary lesions under X-ray fluoroscopy. 2014 , 44, 257-62	11
1091	nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. 2014 , 14, 129-41	13
1090	KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. 2014 , 13, 1611-24	37
1089	Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance. 2014 , 88, 262-4	8
1088	Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer. 2014 , 41, 93-100	9
1087	Invasive and noninvasive advances in the staging of lung cancer. 2014 , 41, 17-27	2
1086	Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. 2014 , 41, 110-25	53
1085	Extending survival of stage IV non-small cell lung cancer. 2014 , 41, 69-92	32
1084	Prognostic and predictive biomarkers in lung cancer. A review. 2014 , 464, 347-58	65
1083	Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. 2014 , 464, 61-8	77
1082	The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma. 2014 , 73, 199-205	16

1081	Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. 2014 , 36, 476-87	12
1080	Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. 2014 , 83, 211-8	53
1079	Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy. 2014 , 343, 74-9	13
1078	Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer. 2014 , 140, 645-52	1
1077	Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. 2014 , 21, 2091-6	55
1076	Immunotherapy for non-small-cell lung cancer: current approaches. 2014 , 3, 19-25	2
1075	Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). 2014 , 32, 377-81	4
1074	Systems analysis of human multigene disorders. Preface. 2014 , 799, v - viii	3
1073	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. 2014 , 11, 282-98	236
1072	Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non-small-cell lung cancer. 2014 , 15, 166-70	24
1071	Recent clinical advances in lung cancer management. <i>Journal of Clinical Oncology</i> , 2014 , 32, 973-82	2.2 169
1070	Effects of exercise training programs on physical performance and quality of life in patients with metastatic lung cancer undergoing palliative chemotherapy--a study protocol. 2014 , 37, 120-8	15
1069	Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer. 2014 , 87, 204-10	4
1068	Survival and prognostic factors in non-small cell lung cancer patients with spinal bone metastases: a retrospective analysis of 303 patients. 2014 , 190, 59-63	19
1067	The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. 2014 , 40, 485-94	19
1066	Carcinome bronchique non ^petites cellules : quelle chimioth�apie de rattrapage ?. 2014 , 6, 442-452	
1065	Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. 2014 , 74, 1149-57	9
1064	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. 2014 , 122, 445-53	38

1063	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. 2014 , 25, 2156-2162		22
1062	LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. 2014 , 10, 533-40		6
1061	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. 2014 , 15, 1379-88		103
1060	Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. 2014 , 85, 401-7		23
1059	A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. 2014 , 86, 59-66		42
1058	Kinetic and mechanistic studies of 1,3-bis(2-pyridylimino)isoindolate Pt(II) derivatives. Experimental and new computational approach. 2014 , 43, 2549-58		20
1057	Immune checkpoint inhibitors in NSCLC. 2014 , 15, 658-69		56
1056	Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1620-9	2.2	45
1055	Molecular characterization may be of PARAMOUNT importance. <i>Journal of Clinical Oncology</i> , 2014 , 32, 481-2	2.2	2
1054	Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3634-42	2.2	52
1053	Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. 2014 , 85, 415-9		16
1052	PARAMOUNT trial: reopening a window to maintenance therapy. <i>Journal of Clinical Oncology</i> , 2014 , 32, 480-1	2.2	2
1051	A Novel of Biodegradable Implants Based on PLGA for Control Delivery of Cisplatin. 2014 , 63, 368-373		4
1050	Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1407-11	2.2	36
1049	Update on systemic therapy of advanced non-small-cell lung cancer. 2014 , 14, 1189-203		19
1048	Reality check for pemetrexed and maintenance therapy in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 482-3	2.2	10
1047	Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study. 2014 , 86, 47-53		
1046	Reply to S. Barni et Al, K.R. Dearing et al, and N. Murray. <i>Journal of Clinical Oncology</i> , 2014 , 32, 483-5	2.2	1

1045	American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1277-80	2.2	273
1044	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. 2014 , 50, 2219-30		29
1043	Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice. 2014 , 50, 2303-8		27
1042	Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architecture. 2014 , 67, 125-131		13
1041	Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. 2014 , 85, 408-14		17
1040	Side effects of targeted therapies. Introduction. 2014 , 30, 137-8		
1039	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. 2014 , 158, 929-944		935
1038	nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update. 2014 , 15, 391-7		9
1037	Resistance to chemotherapy: patient variability and cellular heterogeneity. 2014 , 74, 4663-70		35
1036	Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients. 2014 , 31, 59		11
1035	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. 2014 , 31, 88		13
1034	LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy. 2014 , 31, 99		9
1033	Lung Cancer in Older Adults. 2014 , 3, 166-174		
1032	Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study. 2014 , 14, 491		9
1031	Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. 2014 , 14, 508		25
1030	Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy. 2014 , 9, 147		5
1029	Combination of stereotactic ablative body radiation with targeted therapies. 2014 , 15, e426-34		28
1028	Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. 2014 , 73, 1217-25		25

1027	Treatment of the postoperative recurrence of lung cancer in octogenarians. 2014 , 44, 1626-32	4
1026	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. 2014 , 32, 955-68	45
1025	Immunotherapy for lung cancer: ongoing clinical trials. 2014 , 10, 91-105	21
1024	Accuracy of fine needle aspiration and core lung biopsies to predict histology in patients with non-small cell lung cancer. 2014 , 31, 967	2
1023	Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. 2014 , 16, 463-8	12
1022	Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification. 2014 , 35, 5905-10	12
1021	Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato. 2014 , 16, 1	2
1020	The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/-high thymidylate synthase expression: a meta-analysis. 2014 , 14, 205	23
1019	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. 2014 , 14, 290	39
1018	Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed. 2014 , 12, 98	10
1017	Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. 2014 , 52, 101-6	5
1016	Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1256-61	2.2 49
1015	Understanding lung cancer molecular subtypes. 2014 , 11, 441-453	1
1014	Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology. 2014 , 59, 308-13	19
1013	New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer. 2014 , 20, 2244-8	43
1012	Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non-squamous cell non-small cell lung cancer in Japan. 2014 , 5, 289-96	2
1011	Pathology in drug discovery and development. 2014 , 232, 99-102	6
1010	[Use of erythropoiesis stimulating agents]. 2014 , 31, 162-72	3

1009	Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01). 2014 , 15, 258-65	16
1008	Molecular testing in oncology: problems, pitfalls and progress. 2014 , 83, 309-15	21
1007	Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells. 2014 , 322, 345-54	12
1006	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. 2014 , 50, 1819-1828	57
1005	Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. 2014 , 15, 173-81	50
1004	Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. 2014 , 15, 202-6	55
1003	Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. 2014 , 5, 4182	172
1002	Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. 2014 , 14, 411-7	13
1001	Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing. 2014 , 26, 468-72	3
1000	Nuclear distribution of claudin-2 increases cell proliferation in human lung adenocarcinoma cells. 2014 , 1843, 2079-88	54
999	Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. 2014 , 85, 230-8	40
998	Assessment of folate receptor- β and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients. 2014 , 15, 320-30.e1-3	14
997	[Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 1) Cytotoxic drug treatment, maintenance therapy, and secondary line treatment]. 2014 , 103, 1306-13	
996	[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy]. 2014 , 103, 699-704	
995	First-line chemotherapy treatment of advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?. 2014 , 9, e82	4
994	Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients. 2014 , 2, 714-718	8
993	Chemotherapy for newly diagnosed inoperable brain metastases from non-small cell lung cancer. 2014 ,	
992	Advances in the treatment of non-small cell lung cancer. 2014 , 12, 764-7	11

991	Systemic and targeted therapies for early-stage lung cancer. 2014 , 21, 21-31	17
990	Ramucirumab: a promising development in advanced non-small cell lung cancer. 2014 , 4, 969-977	
989	Adjuvant Chemotherapy Following Surgery for Lung Cancer. 2014 , 278-289	
988	Tumor Microenvironment, Angiogenesis Biology, and Targeted Therapy. 2014 , 505-526	
987	Pathology of Adenocarcinoma. 2014 , 144-157	
986	Learning curve for endobronchial ultrasound-guided transbronchial needle aspiration: experience of a community-based teaching hospital. 2014 , 10, 2441-6	1
985	Pemetrexed in non-small-cell lung cancer. 2014 , 3, 273-285	1
984	Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction. 2014 , 45, 1769-77	15
983	The role of autophagy induced by pemetrexed in lung adenocarcinoma cells. 2014 , 31, 2365-70	8
982	Circulating endothelial cells as a biomarker in non-small cell lung cancer patients: correlation with clinical outcome. 2014 , 29, e337-44	10
981	A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer. 2014 , 7, 435-43	4
980	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. 2014 , 390-405	
979	Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative. 2014 , 21, 90-7	5
978	Early-stage non-small-cell lung cancer: overview of adjuvant chemotherapy and promising advances. 2014 , 3, 85-99	
977	Looking backwards to move forward: a review of randomized lung cancer treatment trials to inform future research. 2014 , 4, 415-428	
976	Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed-resistant lung adenocarcinoma A549 cell line. 2014 , 31, 1818-24	10
975	Effect of nitric oxide synthase on multiple drug resistance is related to Wnt signaling in non-small cell lung cancer. 2014 , 32, 1703-8	15
974	Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study. 2015 , 27, 221-6	9

973	Spontaneous regression of non-small cell lung cancer that progressed after multiple chemotherapies: A case report. 2015 , 6, 805-7	5
972	Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cells. 2015 , 10, 2652-2656	14
971	Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma. 2015 , 46, 505-12	10
970	FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. 2015 , 46, 999-1006	30
969	Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer. 2015 , 38, 1192-8	13
968	Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids. 2015 , 38, 1752-6	5
967	The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials. 2015 , 10, 1523-31	13
966	Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis. 2015 , 5, e006321	4
965	Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. 2015 , 9, 2577-2582	3
964	Expressions of Thyroid Transcription Factor-1, Napsin A, p40, p63, CK5/6 and Desmocollin-3 in Non-Small Cell Lung Cancer, as Revealed by Imprint Cytology Using a Malinol-Based Cell-Transfer Technique. 2015 , 59, 457-64	5
963	Medical Oncology Principles for the Spine Oncology Surgeon. 2015 ,	
962	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. 2015 , 17, 1020-9	37
961	microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer. 2015 , 15, 85	28
960	An der Schwelle zu einem neuen Zeitalter. 2015 , 18, 96-97	
959	Educational outcomes in the era of the Affordable Care Act: impact of personalized education about non-small cell lung cancer. 2015 , 35 Suppl 1, S5-12	1
958	Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. 2015 , 94, e249	2
957	Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. 2015 , 39, 1170-80	49
956	Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer. 2015 , 15, 132	18

955	Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer. 2015 , 10, 63	20
954	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. 2015 , 121, 3212-3220	119
953	Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. 2015 , 22, 193-9	14
952	Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues. 2015 , 30, e234-42	3
951	Lung cancer presenting as a metastasis to the tibial bones: a case report. 2015 , 101, e18-20	3
950	Management of cancer of the lung. 413-426	
949	Defining the issues in the treatment of elderly patients with advanced non-small-cell lung cancer. 2015 , 4, 17-30	
948	Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. 2015 , 121, 2562-9	56
947	Chemotherapy for Advanced-Stage Non-Small Cell Lung Cancer. 2015 , 21, 366-70	35
946	The Evolution of Therapies in Non-Small Cell Lung Cancer. 2015 , 7, 1815-46	81
945	Widespread renal polycystosis induced by crizotinib. 2015 , 101, e128-31	4
944	Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report. 2015 , 9, 2874-2878	1
943	TERT Polymorphism rs2853669 Influences on Lung Cancer Risk in the Korean Population. 2015 , 30, 1423-8	20
942	An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre. 2015 , 22, e157-63	4
941	Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified. 2015 , 22, e164-70	17
940	The distinctive nature of adenocarcinoma of the lung. 2015 , 8, 2399-406	12
939	Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFR. 2015 , 62, 996-1004	1
938	Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. 2015 , 8, 63-79	21

937	Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?. 2015 , 22, 272-8		8
936	A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. 2015 , 9, 4989-96		43
935	Ready or not? Lung cancer diagnosis in 2015. 2015 , 22, 239-42		2
934	Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation. 2015 , 26, 573-8		5
933	Squamous non-small cell lung cancer as a distinct clinical entity. 2015 , 38, 220-6		23
932	Medical management of lung cancer: Experience in China. 2015 , 6, 10-6		30
931	Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. 2015 , 11, 865-78		12
930	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. 2015 , 16, 763-74		329
929	Non-small-cell lung cancer. 2015 , 1, 15009		352
928	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. 2015 , 89, 1227-40		28
927	Frñie palliative Intervention. 2015 , 18, 46-50		
926	A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. 2015 , 26, 1401-8		58
925	Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1008-14	2.2	134
924	Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma. 2015 , 63, 507-13		26
923	Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly. 2015 , 10, e0126357		23
922	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. 2015 , 11, 2175-91		4
921	Necitumumab for non-small cell lung cancer. 2015 , 15, 1231-9		14
920	Dñembrement des adñhocarcinomes bronchopulmonaires : le point de vue du pathologiste. 2015 , 7, 290-305		

919	Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2015 , 16, e131-40	7
918	Radiation therapy (RT) and chemotherapy (CHT) in stage II non-small cell lung cancer (NSCLC): Clinical entity neglected by radiation oncologists?. 2015 , 90, 622-3	
917	The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review. 2015 , 94, e1451	16
916	Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system. 2015 , 27, 371-7	0
915	Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. 2015 , 89, 294-300	18
914	[Non-small cell lung cancer. New biomarkers for diagnostics and therapy]. 2015 , 36 Suppl 2, 189-93	2
913	Therapeutic options in advanced squamous cell lung carcinoma. 2015 , 4, 75-86	
912	Traitement de 1re ligne des cancers bronchopulmonaires non ^ petites cellules de stade IV en l'absence d'addiction oncogñique. 2015 , 7, 404-413	
911	Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells. 2015 , 47, 2296-303	25
910	Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-B-mediated survival signaling pathways in human gallbladder cancer cells. 2015 , 33, 1683-90	10
909	Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1. 2015 , 33, 2411-9	16
908	Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. 2015 , 24, 582-93	19
907	Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002. 2015 , 88, 201-7	5
906	Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. 2015 , 23, 1699-708	91
905	Developing biomarker-specific end points in lung cancer clinical trials. 2015 , 12, 135-46	36
904	Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. 2015 , 16, 137-43	8
903	Emerging drugs for squamous cell lung cancer. 2015 , 20, 149-60	14
902	Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone. 2015 , 32, 464	26

8901	Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. 2015 , 1855, 193-201	9
900	Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. 2015 , 87, 176-85	39
899	Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. 2015 , 87, 193-200	65
898	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. 2015 , 121, 883-92	49
897	Downregulation of MTSS1 expression is an independent prognosticator in squamous cell carcinoma of the lung. 2015 , 112, 866-73	20
896	Image-derived biomarkers and multimodal imaging strategies for lung cancer management. 2015 , 42, 634-43	14
895	Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy. 2015 , 141, 119-25	17
894	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. 2015 , 11, 409-20	28
893	Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?. 2015 , 87, 155-61	7
892	A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. 2015 , 26, 762-768	61
891	A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. 2015 , 70, 359-67	89
890	What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. 2015 , 11, 153-67	20
889	Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2015 , 33, 870-6	2.2 139
888	Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. 2015 , 87, 232-40	17
887	The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). 2015 , 36, 2491-9	7
886	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. 2015 , 16, e83-9	31
885	Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. 2015 , 20, 299-306	10
884	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. 2015 , 34, 129-44	9

883	Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R1 resection) in non-small-cell lung cancer. 2015 , 15, 36		7
882	Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer. 2015 , 20, 659-67		0
881	A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. 2015 , 26, 354-62		98
880	Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. 2015 , 16, 262-73		36
879	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. 2015 , 88, 215-22		48
878	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. 2015 , 10, e0125037		7
877	Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer. 2015 , 6, 13-25		7
876	The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine. 2015 , 5, 20		2
875	Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study. 2015 , 16, 496-506		3
874	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2563-77	2.2	599
873	Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population. 2015 , 27, 505-13		3
872	Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. 2015 , 5, e355-63		18
871	Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. 2015 , 89, 301-5		9
870	CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status. 2015 , 16, 447-56		9
869	Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. 2015 , 94, 213-27		42
868	Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer. 2015 , 4, 106-112		5
867	Achieving a tissue diagnosis in PS3 patients with advanced lung cancer: what are the safety and diagnostic outcomes with EBUS?. 2015 , 88, 236-7		1
866	Glucocorticoid Signaling. 2015 ,		8

865	Glucocorticoids and Cancer. 2015 , 872, 315-33	97
864	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2450-6	2.2 55
863	Epigenetic Therapy in Lung Cancer and Mesothelioma. 2015 , 189-213	4
862	Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. 2015 , 22, e183-215	50
861	Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. 2015 , 16, 1245-53	35
860	Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic cancers of the head and neck; superior outcomes in oropharyngeal primaries. 2014 , 4, 362	2
859	Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients. 2015 , 88, 319-24	4
858	Tropical Hemato-Oncology. 2015 ,	2
857	Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). 2015 , 112, 260-5	8
856	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. 2015 , 45, 55-66	23
855	Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). 2015 , 88, 160-6	7
854	Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design. 2015 , 45, 511-24	4
853	5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis. 2015 , 9, 1815-24	17
852	Best practice in the treatment of advanced squamous cell lung cancer. 2015 , 9, 224-35	14
851	Stereotactic body radiotherapy for oligometastatic disease. 2015 , 27, 290-7	22
850	Factors Influencing the Diagnostic Accuracy of Identifying the Histologic Type of Non--Small-Lung Cancer With Small Samples. 2015 , 16, 374-8	4
849	Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. 2015 , 87, 226-31	30
848	Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility. 2015 , 87, 296-302	1

847	Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System. 2015 , 16, e213-21	15
846	[Molecular diagnostics of non-small cell lung cancer: New markers and technologies]. 2015 , 36, 154-63	3
845	Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. 2015 , 36, 861-9	7
844	Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer. 2015 , 36, 1323-7	6
843	Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients. 2015 , 36, 7151-7	3
842	Addressing the unmet need in lung cancer: The potential of immuno-oncology. 2015 , 41, 465-75	25
841	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. 2015 , 16, 358-65	13
840	Refining the treatment of NSCLC according to histological and molecular subtypes. 2015 , 12, 511-26	189
839	Squamous cell lung cancer: from tumor genomics to cancer therapeutics. 2015 , 21, 2236-43	96
838	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. 2015 , 9, 255-68	21
837	Targeted Therapies for Solid Tumors. 2015 ,	1
836	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. 2015 , 16, 328-37	102
835	Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy. 2015 , 25, 122-32	7
834	Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. 2015 , 46, 219-29	11
833	Targeting of MEK in lung cancer therapeutics. 2015 , 3, 319-27	31
832	FGFR as potential target in the treatment of squamous non small cell lung cancer. 2015 , 41, 527-39	46
831	KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. 2015 , 38, 33-40	34
830	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. 2015 , 16, e165-72	477

829	Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. 2015 , 10, 586-94		31
828	Semiautomatic determination of arterial input functions for quantitative dynamic contrast-enhanced magnetic resonance imaging in non-small cell lung cancer patients. 2015 , 50, 129-34		3
827	Associations of blood pressure with common factors among left-behind farmers in rural China: a cross-sectional study using quantile regression analysis. 2015 , 94, e142		7
826	PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. 2015 , 10, 134-42		109
825	Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. 2015 , 26, 456-63		4
824	Management of metastatic cervical cancer: should we ignore lessons learned from treating other advanced squamous cell cancers?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 965-6	2.2	2
823	Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. 2015 , 10, 353-9		18
822	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. 2015 , 27, 94-101		102
821	Improvement in lung cancer outcomes with targeted therapies: an update for family physicians. 2015 , 28, 124-33		21
820	Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis. 2015 , 75, 1163-73		6
819	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). 2015 , 20, 370-8		92
818	Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. 2015 , 20, 975-8		4
817	Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. 2015 , 16, 1630-8		62
816	Nedaplatin: a new platinum for squamous lung cancer?. 2015 , 16, 1573-4		4
815	Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. 2015 , 20, 1175-81		21
814	miR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent protein kinase-1 in non-small cell lung cancer cells. 2015 , 9, 27-33		51
813	Pharmacogenomics in the treatment of lung cancer: an update. 2015 , 16, 1751-60		4
812	Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations. 2015 , 90, 620-2		1

811	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. 2015 , 113, 1519-28		70
810	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). 2015 , 26, 1547-73		451
809	Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. 2015 , 11, 489-500		17
808	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3488-515	2.2	363
807	Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration. 2015 , 16, 47		6
806	Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. 2015 , 90, 71-7		26
805	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. 2015 , 90, 261-6		4
804	The evolving role of radiotherapy in treatment of oligometastatic NSCLC. 2015 , 15, 1459-71		7
803	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. 2015 , 16, 366-73		19
802	Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. 2015 , 16, 514-22		8
801	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. 2015 , 23, 20-54		38
800	In Reply. 2015 , 20, e22		
799	Radiation therapy for oligometastatic non-small cell lung cancer. 2015 , 34, 183-93		10
798	Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. 2015 , 15, 121-8		2
797	Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo. 2015 , 91, 91-9		31
796	Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer. 2015 , 27, 30-9		21
795	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. 2015 , 87, 34-8		23
794	Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer. 2015 , 11, 263-73		19

793	The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. 2015 , 123, 108-15	45
792	ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway. 2015 , 136, 2598-609	38
791	Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. 2015 , 36, 1561-6	17
790	New Therapeutic Strategies in Lung Cancers. 2015 ,	0
789	Some considerations about the value based pricing in oncology: an analysis on metastatic first line medicinal products. 2016 , 3, 9-15	1
788	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. 2016 , 11, 87-92	1
787	Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma. 2016 , 63, 282-7	1
786	Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. 2016 , 7, 83-90	4
785	Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. 2016 , 7, 1515-23	5
784	Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level. 2016 , 9, 4527-31	2
783	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. 2016 , 9, 3187-95	11
782	New targeted treatments for non-small-cell lung cancer - role of nivolumab. 2016 , 10, 103-17	18
781	Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. 2016 , 9, 4639-44	6
780	Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study. 2016 , 8, 97-111	0
779	Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. 2016 , 7, 53245-53253	86
778	Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology. 2016 , 12, 1215-1218	2
777	A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting. 2016 , 8, E1520-E1524	
776	Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?. 2016 , 5, 538-542	4

775	State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. 2016 , 5, 599-609	15
774	Metastatic lung cancer in the age of targeted therapy: improving long-term survival. 2016 , 5, 727-730	11
773	Current advances of endobronchial ultrasonography in the diagnosis and staging of lung cancer. 2016 , 8, S690-S696	7
772	A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. 2016 , 28, 444-51	19
771	An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer. 2016 , 7, 86561-86572	24
770	Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM. 2016 , 8, E607-10	2
769	The role of surgical intervention in lung cancer with carcinomatous pleuritis. 2016 , 8, S901-S907	7
768	Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. 2019 , 12, 640-645	8
767	Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial. 2019 , 125, 2203-2212	5
766	Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors. 2019 , 151-171	
765	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. 2019 , 15, 1363-1383	8
764	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. 2019 , 11,	35
763	Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer. 2019 , 8, 1434-1441	8
762	Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?. 2019 , 4, e000483	13
761	Traitements de première ligne dans les CBNPC avancés, en l'absence d'addiction oncogénique (incluant le traitement de maintenance et les anti-angiogéniques). 2019 , 11, 342-354	
760	Mechanisms of resistance to pemetrexed in non-small cell lung cancer. 2019 , 8, 1107-1118	20
759	Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer.. 2019 , 8, E11-E14	
758	Cancers bronchiques de stade III: rôle de l'enco-radiothérapie. 2019 , 11, 278-289	

757	Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy. 2019 , 55,	
756	KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?. 2019 , 8, 723-727	2
755	Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. 2019 ,	78
754	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. 2019 ,	0
753	Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching. 2019 , 30, 295-301	2
752	Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer. 2019 , 14, 229	4
751	The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials. 2019 , 11, 4453-4463	3
750	Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. 2019 , 19, 317	8
749	Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. 2019 , 11, 10083-10092	4
748	A phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancer. 2019 , 11, 4529-4537	5
747	Creating a Synthetic Clinical Trial: Comparative Effectiveness Analyses Using an Electronic Medical Record. 2019 , 3, 1-10	2
746	Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States. 2019 , 11, 4474-4483	2
745	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. 2019 , 444, 147-161	9
744	Design and Application of Cisplatin-Loaded Magnetic Nanoparticle Clusters for Smart Chemotherapy. 2019 , 11, 1864-1875	31
743	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. 2019 , 30, 171-210	121
742	Cancer and AIDS. 2019 ,	
741	Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes. 2019 , 45, 838-844	4
740	Gene Fusion in NSCLC. 2019 , 443-464	

739	Correct and logical inference on efficacy in subgroups and their mixture for binary outcomes. 2019 , 61, 8-26	9
738	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). 2019 , 21, 3-17	51
737	Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. 2019 , 37, 498-506	3
736	Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. 2019 , 14, 212-222	55
735	Metal-based antitumor compounds: beyond cisplatin. 2019 , 11, 119-135	46
734	Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. 2019 , 129, 35-40	77
733	Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome. 2019 , 19, 70	4
732	miR-210 promotes lung adenocarcinoma proliferation, migration, and invasion by targeting lysyl oxidase-like 4. 2019 , 234, 14050-14057	18
731	LUBAC determines chemotherapy resistance in squamous cell lung cancer. 2019 , 216, 450-465	35
730	ZWINT is the next potential target for lung cancer therapy. 2019 , 145, 661-673	16
729	Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats. 2019 , 166, 244-251	5
728	A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. 2019 , 37, 658-665	6
727	Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. 2019 , 22, 140-150	16
726	Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report. 2019 , 25, 2007-2009	0
725	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). 2019 , 20, 43-47	32
724	Computational Drug Repositioning with Random Walk on a Heterogeneous Network. 2019 , 16, 1890-1900	18
723	Internal Medicine Residents' Perception of Cancer Prognosis. 2020 , 35, 983-987	1
722	An advanced c-MET-amplified NSCLC patient that was treated with crizotinib. 2020 , 26, 474-477	1

721	Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. 2020 , 119, 1731-1741	30
720	Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells. 2020 , 108, 300-311	3
719	Classification and Imaging Findings of Lung Neoplasms. 2020 , 55, 41-50	1
718	Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein. 2020 , 235, 3309-3319	11
717	Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients. 2020 , 26, 761-767	8
716	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. 2020 , 22, 708-716	4
715	Cancer of the Lung: NonSmall Cell Lung Cancer and Small Cell Lung Cancer. 2020 , 1108-1158.e16	5
714	Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials. 2020 , 107, 369-377	34
713	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. 2020 , 9, 4430-4445	
712	Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3. 2020 , 66, 153109	4
711	Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. 2020 , 25, 274-281	4
710	Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. 2020 , 21, 9-16	4
709	Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. 2020 , 126, 1717-1726	12
708	Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry. 2020 , 34, 369-379	2
707	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. 2020 , 146, 102858	28
706	Platinum-based combination chemotherapy triggers cancer cell death through induction of BNIP3 and ROS, but not autophagy. 2020 , 24, 1993-2003	13
705	Twenty-five years of Respiriology: Advances in lung cancer. 2020 , 25, 26-31	2
704	Precision Medicine in Lung Cancer Treatment. 2020 , 29, 15-21	10

703	The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung. 2020 , 125, 19-29		5
702	S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan. 2020 , 16, e68-e73		0
701	Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug Z-pemetrexed in lung adenocarcinoma Xenografts. 2020 , 38, 1031-1043		2
700	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2020 , 38, 793-803	2.2	12
699	Regulation of MicroRNA-497-Targeting AKT2 Influences Tumor Growth and Chemoresistance to Cisplatin in Lung Cancer. 2020 , 8, 840		4
698	The Role of Surgery in Lung Cancer Treatment. 2020 , 12,		
697	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. 2020 , 12,		4
696	First-line cytotoxic chemotherapy regimen for non-small cell lung cancer in the elderly population: plus a change. 2020 , 9, 1591-1594		
695	Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study. 2020 , 11, 3641-3644		2
694	Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry. 2020 , 11, 3346-3356		1
693	Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. 2020 , 111, 3739-3746		7
692	KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). 2020 , 11, 3425-3435		5
691	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. 2020 , 25, e1930-e1955		4
690	Traitements systémiques de première ligne dans les CBNPC avancés en l'absence d'addiction oncogénique. 2020 , 12, 2S173-2S184		
689	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. 2020 , 12, 1758835920936882		7
688	Predictors of Acquired Mutation in Patients Failing First- or Second-Generation -Tyrosine Kinase Inhibitors. 2020 , 12, 5439-5450		4
687	Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis. 2020 , 8, 1288		2
686	Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial. 2020 , 8, 1315		

685	Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer. 2020 , 38, 608-617	0
684	Diagnostic patterns of non-small-cell lung cancer at Princess Margaret Cancer Centre. 2020 , 27, 244-249	2
683	First line Immunotherapy for Non-Small Cell Lung Cancer. 2020 , 13,	19
682	A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis. 2020 , 20, 548	2
681	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). 2020 , 15, 1636-1646	75
680	Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective Study. 2020 , 12, 6033-6044	
679	The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLC: Matter as Actual Now as in the Past. 2020 , 8, 936	
678	Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. 2020 , 12,	3
677	Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer. 2020 , 14, 2945-2957	2
676	Vinorelbine in Non-Small Cell Lung Cancer: Real-World Data From a Single-Institution Experience. 2020 , 28, 237-248	0
675	Lung cancer and intraocular metastasis in gestation: Clinical experiences of a rare case. 2020 , 11, 2723-2726	0
674	HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. 2020 , 10, 1162	3
673	BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness. 2020 , 12,	5
672	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study. 2020 , 147, 229-236	3
671	Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer. 2020 , 11, 2536-2541	3
670	Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver. 2020 , 9, LMT36	7
669	Management of cisplatin-associated toxicities in bladder cancer patients. 2020 , 14, 286-292	1
668	Network meta-analyses for EGFR mutation-positive non-small-cell lung cancer: systematic review and overview of methods and shortcomings. 2020 , 9, 1179-1194	0

667	Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma. 2020 , 11, 1188	5
666	Capmatinib in Exon 14-Mutated or -Amplified Non-Small-Cell Lung Cancer. 2020 , 383, 944-957	214
665	Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. 2020 , 25,	7
664	Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma. 2020 , 10, 1568	1
663	Prognostic value of log odds of positive lymph nodes in node-positive lung squamous cell carcinoma patients after surgery: a SEER population-based study. 2020 , 9, 1285-1301	12
662	Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. 2020 , 20, 875	15
661	Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer. 2020 , 15, 1556-1558	4
660	The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis. 2020 , 10, 1636	0
659	Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases. 2020 , 26, 2069-2072	1
658	An Activatable Nano-Prodrug for Treating Tyrosine-Kinase-Inhibitor-Resistant Non-Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging. 2020 , 16, e2003451	12
657	Variants of Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. 2020 , 40, 4245-4251	3
656	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. 2020 , 20, 590	
655	Changing paradigm in advanced and metastatic non-small cell lung cancer. 2020 , 12, 6992-7001	2
654	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi [®] , AstraZeneca UK Limited). 2020 , 123, 18-27	5
653	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer. 2020 , 26, 517-524	5
652	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. 2020 , 12, CD013257	12
651	Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study. 2020 , 6,	1
650	Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). 2020 , 17,	7

649	Hematologic adverse drug reactions leading to hospitalization among cancer patients: A retrospective case-control study. 2020 , 83, 784-790		
648	Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer. 2020 , 40, 6399-6406		1
647	Desmoglein 3 and Keratin 14 for Distinguishing Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. 2020 , 13, 11111-11124		3
646	Classifying non-small cell lung cancer types and transcriptomic subtypes using convolutional neural networks. 2020 , 27, 757-769		25
645	Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells. 2020 , 40, 1451-1458		6
644	Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. 2020 , 10, 8159		10
643	GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. 2020 , 26, 4901-4910		74
642	A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. 2020 , 40, 2981-2987		3
641	LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression. 2020 , 19, 98		48
640	Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. 2020 , 21, e607-e621		7
639	PNO1, which is negatively regulated by miR-340-5p, promotes lung adenocarcinoma progression through Notch signaling pathway. 2020 , 9, 58		10
638	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2187-2196	2.2	32
637	Systemic treatment of brain metastases in non-small cell lung cancer. 2020 , 132, 187-198		24
636	Adjuvant Chemotherapy. 2020 , 30, 179-185		0
635	Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed. 2020 , 76, 1573-1580		1
634	Lung cancer histology-driven strategic therapeutic approaches. 2020 , 4, 29-29		2
633	The top 100 cited articles in lung cancer - a bibliometric analysis. 2020 , 24, 17-28		3
632	Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors. 2020 , 12, 2859-2876		6

631	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. 2020 , 6, e196828		17
630	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1505-1517	2.2	298
629	Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. 2020 , 11, 331		16
628	Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquid-based cytology for lung cancer at bronchoscopic examinations. 2020 , 48, 516-523		8
627	First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. 2020 , 9, 3310-3318		10
626	The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer. 2020 , 11, 17		2
625	First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients. 2020 , 21, e572-e582		
624	Rechallenge Strategy in Cancer Therapy. 2020 , 98, 669-679		4
623	Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma. 2020 , 17, 1393-1405		5
622	Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial. 2020 , 9, 2621-2630		5
621	A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. 2020 , 148, 102896		6
620	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. 2020 , 21, 679-686		1
619	Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina. 2020 , 21, e380-e387		12
618	The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. 2020 , 58, 269-274		0
617	Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma. 2020 , 125, 109958		2
616	Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. 2020 , 21, e349-e354		8
615	Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. 2020 , 119, 1506-1513		1
614	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. 2020 , 26, 47-51		134

613	A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. 2020 , 26, 1796-1802	3
612	Precision Management of Advanced Non-Small Cell Lung Cancer. 2020 , 71, 117-136	52
611	Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. 2020 , 1, CD009256	14
610	Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study. 2020 , 141, 64-71	7
609	The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. 2020 , 147, 1163-1179	8
608	Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. 2020 , 21, 373-386	148
607	Pulmonary artery coil embolisation prevented tumour progression in a patient with advanced squamous cell lung carcinoma. 2020 , 125, 257-261	
606	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. 2020 , 6, 661-674	205
605	Is tissue still the issue in detecting molecular alterations in lung cancer?. 2020 , 25, 933-943	14
604	Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan. 2020 , 21, 211-221	0
603	Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. 2020 , 12, 35	10
602	Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines Initiative. 2020 , 108, 817-825	5
601	Aberrant static and dynamic functional connectivity of the executive control network in lung cancer patients after chemotherapy: a longitudinal fMRI study. 2020 , 14, 927-940	7
600	Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. 2020 , 111, 1910-1920	11
599	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. 2020 , 12, 639-650	4
598	Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020. 2020 , 27, 52-60	8
597	Acetyl-11-keto- β -oswellic acid enhances the cisplatin sensitivity of non-small cell lung cancer cells through cell cycle arrest, apoptosis induction, and autophagy suppression via p21-dependent signaling pathway. 2021 , 37, 209-228	10
596	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. 2021 , 11,	8

595	Histogram Analysis of ADC Maps for Differentiating Brain Metastases From Different Histological Types of Lung Cancers. 2021 , 72, 271-278	3
594	Development, internal validation and calibration of a risk score to predict survival in patients with -mutant non-small cell lung cancer. 2021 , 74, 116-122	3
593	Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. 2021 , 26, 507-514	0
592	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. 2021 , 7, 15-28	27
591	Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers). 2021 , 18, 103-118	4
590	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. 2021 , 124, 281-289	11
589	Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations. 2021 , 22, 32-41.e1	2
588	Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302. 2021 , 26, 515-522	2
587	2020 Innovation-Based Optimism for Lung Cancer Outcomes. 2021 , 26, e454-e472	4
586	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. 2021 , 16, 653-664	68
585	Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States. 2021 , 37, 469-476	0
584	Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis. 2021 , 13, 17588359211018537	2
583	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib. 2021 , 17, 36	
582	Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). 2021 , 13, 17588359211022905	0
581	The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification. 2021 , 53, 1024-1032	1
580	A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. 2021 , 34, 101478	0
579	Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis. 2021 , 16, 183-191	2
578	An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance. 2021 , 11, 5346-5364	4

577	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. 2021 , 10, 202-220	13
576	Analysis of bevacizumab treatments and metastatic sites of lung cancer. 2021 , 26, 100290	2
575	Survival prediction for non-small cell lung cancer patients treated with CT-guided microwave ablation: development of a prognostic nomogram. 2021 , 38, 640-649	4
574	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. 2021 , 28, 100416	
573	Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy. 2021 , 38, 6	1
572	Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. 2021 , 10, 563-580	6
571	An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer. 2021 , 99, 389-396	0
570	Detecting TYMS Tandem Repeat Polymorphism by the PSSD Method Based on Next-generation Sequencing. 2021 , 15, 1153-1159	1
569	miR-31 Displays Subtype Specificity in Lung Cancer. 2021 , 81, 1942-1953	1
568	Carcinoma de pulmão no microcítico. 2021 , 13, 1377-1387	1
567	Uncovering the Pharmacological Mechanism of 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione Against Lung Cancer Based on Network Pharmacology and Experimental Evaluation. 2021 , 12, 617555	0
566	Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. 2021 , 9, 206	0
565	Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. 2021 , 6, 100013	1
564	Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: A single-arm, open-label, multicenter, phase II study. 2021 , 17, 486-494	1
563	High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. 2021 , 19, 92	2
562	Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced -Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. 2021 , 2, 100131	0
561	The Gustave Roussy Immune (GRIIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. 2021 , 10,	12
560	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. 2021 , 13, 1813-1821	0

559	Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer. 2021 , 11, 620154	
558	Analysis of Chronic Mild Stress-Induced Hypothalamic Proteome: Identification of Protein Dysregulations Associated With Vulnerability and Resiliency to Depression or Anxiety. 2021 , 14, 633398	5
557	Lung cancer chemotherapy using nanoparticles: Enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. 2021 , 136, 111249	4
556	Overcoming therapy resistance in EGFR-mutant lung cancer.. 2021 , 2, 377-391	23
555	Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions. 2021 , 13,	0
554	PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression $\geq 50\%$: Selecting the best strategy. 2021 , 160, 103302	6
553	Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases. 2021 , 11, 644282	0
552	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. 2021 , 4, CD013257	8
551	Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. 2021 , 13,	3
550	Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. 2021 , 11, 8551	2
549	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. 2021 , 7, 709-717	45
548	Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study. 2021 , 32, 767-772	0
547	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine + cisplatin in patients with advanced solid tumours. 2021 , 125, 510-519	16
546	The macrophage reprogramming ability of antifolates reveals soluble CD14 as a potential biomarker for methotrexate response in rheumatoid arthritis.	
545	Current advances in the treatment of lung cancer with immune checkpoint inhibitors. 2021 , 64, 333-341	
544	The expression of Nanog protein and fibroblast growth factor-inducible molecule 14 in patients with non-small cell lung cancer and their relationship with pathological characteristics and prognosis.. 2021 , 10, 2470-2477	1
543	Improving the Subtype Classification of Non-small Cell Lung Cancer by Elastic Deformation Based Machine Learning. 2021 , 34, 605-617	0
542	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. 2021 , 4, e2111113	5

541	The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials. 2021 , 12, 582447	4
540	The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events. 2021 , 155, 191-192	
539	circCCND1 Regulates Oxidative Stress and FGF9 to Enhance Chemoresistance of Non-Small Cell Lung Cancer via Sponging miR-187-3p. 2021 , 40, 675-682	4
538	Long-Term Survival Effect of the Interval between Postoperative Chemotherapy and Radiotherapy in Patients with Completely Resected Pathological N2 Non-Small-Cell Lung Cancer. 2021 , 13,	0
537	Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report. 2021 , 22, 175	1
536	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. 2021 , 155, 53-60	2
535	Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia. 2021 , 14, 437-448	8
534	Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. 2021 , 21, 495	3
533	Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model. 2021 , 9, 688062	5
532	Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer. 2021 , 160, 2293-2303	2
531	Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms. 2021 , 17, e1460-e1472	0
530	Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. 2021 , 156, 41-49	12
529	One carbon metabolism in human lung cancer. 2021 , 10, 2523-2538	2
528	Evaluation of Computer-Aided Nodule Assessment and Risk Yield (CANARY) in Korean patients for prediction of invasiveness of ground-glass opacity nodule. 2021 , 16, e0253204	
527	Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety. 2021 , 100, e25709	2
526	Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. 2021 , 22, 72	1
525	Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. 2021 , 156, 91-99	2
524	Predictive Radiomic Models for the Chemotherapy Response in Non-Small-Cell Lung Cancer based on Computerized-Tomography Images. 2021 , 11, 646190	4

523	A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. 2021 , 157, 21-29	3
522	Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial. 2021 , 12, 2345-2351	1
521	Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open-label phase 2 study (CLEAR). 2021 , 10, 3059-3070	
520	Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014. 2021 , 22, e602-e611	1
519	The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis. 2021 , 96, 107594	5
518	Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis. 2021 , 12, 2300-2306	1
517	Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. 2021 , 16, 1952-1958	7
516	Update on recent key publications in lung oncology: picking up speed. 2021 , 30,	0
515	Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. 2021 , 11,	1
514	Cancer-associated fibroblast-derived CCL5 contributes to cisplatin resistance in A549 NSCLC cells partially through upregulation of lncRNA HOTAIR expression. 2021 , 22, 696	7
513	Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy. 2021 , 17, 2940-2949	1
512	Toward personalized treatment approaches for non-small-cell lung cancer. 2021 , 27, 1345-1356	43
511	Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer. 2021 , 10, 6642-6652	3
510	Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors. 2021 , 29, 100369	0
509	The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. 2021 , 1	1
508	PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis. 2021 , 17, 4415-4424	0
507	Global effects of RAB3GAP1 dysexpression on the proteome of mouse cortical neurons. 2021 , 53, 1339-1350	0
506	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. 2021 , 2, 100208	

505	Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. 2021 , 12, 772	5
504	A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors. 2021 , 149, 2063-2074	1
503	Palm Pustules Induced by Pemetrexed. 2021 , 16, 1589-1591	
502	Post-chemotherapy and targeted therapy imaging of the chest in lung cancer. 2021 ,	2
501	The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy. 2021 , 14, 1193-1203	
500	Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway. 2021 , 64, 1814-1828	1
499	A Comprehensive Review of Current Perspectives on Novel Drug Delivery Systems and Approaches for Lung Cancer Management. 1	2
498	Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma. 2021 , 12, 718675	1
497	Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib. 2021 , 12, 366-368	1
496	Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells. 2021 , 20, 2527-2538	0
495	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). 2021 , 16, 1501-1511	24
494	Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial. 2021 , 6, 100249	0
493	Comparative Proteomics of Rat Olfactory Bulb Reveal Insights into Susceptibility and Resiliency to Chronic-stress-induced Depression or Anxiety. 2021 , 473, 29-43	0
492	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. 2021 , 161, 180-188	1
491	Efficacy and Safety of Lipegfilgrastim in Lung Cancer Patients Receiving Myelosuppressive Chemotherapy in a Real-World Setting: Results of an Analysis of Pooled Data from Two Non-Interventional European Studies. 2021 , 44, 93-102	0
490	Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type.. 2021 , 10, 184-194	
489	A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. 2021 , 13, 1758835921996506	
488	Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach. 2021 , 2279, 91-107	

487	Lung Cancer. 2021 ,	
486	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. 2020 , 10, 590356	1
485	Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer. 2021 , 53, 87-92	
484	Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!. 2021 , 476, 1365-1375	2
483	Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades. 2021 , 2021, 7836264	4
482	Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer. 2020 , 3, e2030442	13
481	Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings. 127-199	5
480	Lung. 203-220	1
479	Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung Cancer. 2021 , 8, 2003263	6
478	Circular RNA hsa_circ_0085131 is involved in cisplatin-resistance of non-small-cell lung cancer cells by regulating autophagy. 2020 , 44, 1945-1956	17
477	A long-term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced non-squamous non-small cell lung cancer. 2021 , 9, 927-931	1
476	Biological Role, Properties, and Therapeutic Applications of the Reduced Folate Carrier (RFC-SLC19A1) and the Proton-Coupled Folate Transporter (PCFT-SLC46A1). 2011 , 1-34	3
475	Folate Receptor Targeted Thymidylate Synthase Inhibitors. 2011 , 93-117	2
474	Immunotherapy. 2017 , 227-237	1
473	NonSmall Cell Lung Cancer. 2012 , 805-838	3
472	Cancer of the Lung. 2014 , 1143-1192.e13	3
471	Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm. 2018 , 30, 23-29	2
470	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-268	4

469	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1 Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2781-2789	2.2	1
468	Surgical Intervention for Patients With Spinal Metastasis From Lung Cancer: A Retrospective Study of 87 Cases. 2021 , 34, E133-E140		6
467	Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. 2012 , 7, 567-73		23
466	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.		1
465	USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinoma.		1
464	Mesothelioma Interactome with 367 Novel Protein-Protein Interactions.		0
463	Classifying Non-Small Cell Lung Cancer Histopathology Types and Transcriptomic Subtypes using Convolutional Neural Networks.		2
462	Chemotherapy. 186-201		1
461	Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer. 2017 , 23, 5683-5689		3
460	Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma. 2013 , 13, 3-18		10
459	Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). 2013 , 13, 202-17		5
458	Tobacco Smoking and Lung Cancer: Perception-changing facts. 2013 , 13, 345-58		54
457	Predicting Prognosis of Early-Stage Non-Small Cell Lung Cancer Using the GeneFxC Lung Signature. 2015 , 7,		3
456	Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. 2009 , 4, e5133		116
455	Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. 2012 , 7, e37229		46
454	The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience. 2012 , 7, e48323		31
453	The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. 2013 , 8, e51780		58
452	Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study. 2013 , 8, e59700		12

451	The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy. 2013 , 8, e61585	8
450	Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis. 2013 , 8, e67929	6
449	EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer. 2013 , 8, e72966	8
448	Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study. 2014 , 9, e107455	7
447	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. 2015 , 10, e0145936	15
446	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). 2016 , 11, e0147599	17
445	Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. 2017 , 12, e0178420	49
444	Pemetrexed-Induced Interstitial Pneumonitis: A Case Study and Literature Review. 2014 , 5, 232-236	5
443	Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. 2016 , 7, 76577-76589	11
442	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. 2017 , 8, 43555-43570	8
441	Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression. 2017 , 8, 61901-61916	9
440	Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis. 2017 , 8, 74554-74566	15
439	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractionated cisplatin and metronomic etoposide and bevacizumab (mPEBev). 2017 , 8, 75904-75913	18
438	evaluation of tumor cell specific drug responses in malignant pleural effusions. 2017 , 8, 82885-82896	3
437	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. 2014 , 5, 4529-42	37
436	Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. 2018 , 9, 5435-5444	4
435	Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer. 2018 , 9, 8573-8583	9
434	Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. 2018 , 9, 16807-16821	17

433	Targeted therapies for advanced non-small cell lung cancer. 2018 , 9, 37589-37607	36
432	A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. 2020 , 11, 3105-3117	8
431	A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. 2015 , 6, 22750-7	5
430	Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. 2012 , 3, 414-25	89
429	Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells. 2015 , 6, 29482-96	39
428	Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance. 2012 , 3, 414-425	143
427	Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. 2015 , 6, 32602-9	13
426	Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. 2016 , 7, 2496-507	27
425	Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. 2016 , 7, 20166-79	11
424	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. 2016 , 7, 40781-40791	6
423	Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. 2016 , 7, 36198-36206	26
422	Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer. 2020 , 17, 444-457	4
421	Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients. 2016 , 4, 381	6
420	The emerging treatment landscape of advanced non-small cell lung cancer. 2018 , 6, 138	24
419	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. 2018 , 6, 143	6
418	Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?. 2018 , 6, 139	24
417	Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?. 2017 , 29, 263-271	5
416	Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study. 2019 , 31, 339-348	4

415	First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China. 2019 , 31, 749-758	4
414	Cancer chemotherapy: targeting folic acid synthesis. 2010 , 2, 293-301	96
413	Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. 2011 , 3, 21-34	2
412	Establishment and Characterization of Pemetrexed-resistant NCI-H460/PMT Cells. 2019 , 19, 731-739	5
411	Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know. 2009 , 5, 837-41	6
410	Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. 2010 , 14, 47-53	6
409	Post-operative chemotherapy with pemetrexed alone for elder patients with non-small cell lung cancer. 2010 , 29, 1432-1434	1
408	[The International Association for the Study of Lung Cancer Staging Project. Prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer]. 2010 , 13, 9-18	9
407	[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. 2010 , 13, 171-89	6
406	[A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer]. 2013 , 16, 405-10	2
405	[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]. 2019 , 22, 369-379	2
404	CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells. 2020 , 56, 1574-1584	8
403	Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non-small cell lung cancer. 2020 , 19, 1031-1041	6
402	Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. 2020 , 19, 1559-1566	26
401	Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC. 2020 , 19, 3859-3870	1
400	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. 2019 , 34, 50-59	9
399	Comparative outcomes of squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of ASA404 (DMXAA) - retrospective analysis of pooled data. 2010 , 2, 199-204	22
398	Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?. 2011 , 3, 19-29	24

397	Treatment of advanced non small cell lung cancer. 2011 , 3, 122-33	69
396	Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. 2012 , 4, 562-8	45
395	Treatment of non-small cell lung cancer (NSCLC). 2013 , 5 Suppl 4, S389-96	109
394	Chemotherapy advances in small-cell lung cancer. 2013 , 5 Suppl 5, S565-78	51
393	The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. 2013 , 5 Suppl 5, S556-64	13
392	Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. 2014 , 6, 356-68	1
391	The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. 2014 , 6, S526-36	33
390	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. 2014 , 6, S502-25	9
389	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. 2014 , 6, 958-64	6
388	Maintenance therapy in non-small-cell lung cancer. 2012 , 1, 105-10	3
387	Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). 2013 , 2, 160-71	11
386	Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). 2013 , 2, 403-10	23
385	Clinical trials for lung cancer in China. 2014 , 3, 311-6	2
384	Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?. 2015 , 4, 223-7	15
383	PROFILE 1014: lessons for the new era of lung cancer clinical research. 2015 , 4, 642-8	8
382	Treatment of advanced squamous cell carcinoma of the lung: a review. 2015 , 4, 524-32	51
381	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. 2015 , 4, 392-403	16
380	Overall survival in non-small cell lung cancer-what is clinically meaningful?. 2016 , 5, 115-9	17

379	Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. 2012 , 1, 508-15	35
378	Pemetrexed induced pneumonitis. 2011 , 1, e106	6
377	Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence. 2016 , 33, 470-2	1
376	Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era. 2015 , 32, 217-22	8
375	Role of Crizotinib in previously treated non-small-cell lung cancer. 2014 , 3, 138-40	3
374	Lung cancer in India: Current status and promising strategies. 2016 , 5, 93-5	18
373	Lung cancer in the Indian subcontinent. 2016 , 5, 95-103	36
372	Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population. 2016 , 5, 196-203	3
371	Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. 2019 , 14, 173-178	5
370	Saudi lung cancer management guidelines 2017. 2017 , 12, 221-246	9
369	Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. 2017 , 54, 89-103	3
368	Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. 2018 , 55, 125-133	2
367	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. 2019 , 8, 1-17	6
366	First-line management of metastatic non-small cell lung cancer: An Indian perspective. 2019 , 8, 73-79	3
365	Phase II Clinical Trial of Genexol \square (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer. 2011 , 43, 19-23	11
364	Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. 2015 , 47, 424-35	4
363	Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer. 2013 , 45, 74-7	11
362	Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. 2015 , 47, 616-29	10

361	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. 2015 , 47, 630-7	17
360	Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. 2016 , 48, 80-7	12
359	Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. 2020 , 52, 292-300	8
358	Safety and efficacy of pemetrexed in gynecologic cancers: A systematic literature review. 2013 , 02, 19-32	6
357	Molecular predictors of gemcitabine response in pancreatic cancer. 2011 , 3, 153-64	54
356	Targeted treatments for metastatic esophageal squamous cell cancer. 2013 , 5, 88-96	7
355	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. 2011 , 2, 367-76	31
354	Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. 2011 , 2, 262-71	7
353	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. 2013 , 4, 29-42	8
352	Apoptosis block as a barrier to effective therapy in non small cell lung cancer. 2014 , 5, 588-94	20
351	Advances in adjuvant systemic therapy for non-small-cell lung cancer. 2014 , 5, 633-45	18
350	The role of BRCA1 in non-small cell lung cancer. 2012 , 156, 200-3	7
349	Association of CYP3A4*1B and CYP3A5*3 genetic polymorphisms with lung cancer and its impact on taxane metabolism in Indian population. 2015 , 2, 19	1
348	Application of cancer genomics to solve unmet clinical needs. 2013 , 11, 174-9	8
347	Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. 2010 , 134, 55-65	25
346	Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer. 2019 , 17, 469-477	10
345	Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer. 2013 , 14, 6267-71	10
344	Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. 2014 , 15, 7453-7	18

343	Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. 2014 , 15, 731-6	13
342	Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer. 2014 , 15, 10967-70	4
341	Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis. 2014 , 15, 3419-24	11
340	Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma. 2015 , 16, 551-7	2
339	Assays for predicting and monitoring responses to lung cancer immunotherapy. 2015 , 12, 87-95	33
338	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. 2015 , 4, 212289	27
337	Lung Cancer. 2021 , 481-515	
336	Cancers bronchiques de stade III : rôle de l'immunothérapie. 2021 , 13, 2S97-2S108	
335	Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique. 2021 , 13, 2S272-2S279	
334	Proteomic Insights Into Susceptibility and Resistance to Chronic-Stress-Induced Depression or Anxiety in the Rat Striatum. 2021 , 8, 730473	0
333	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials. 2021 , 12, 686876	0
332	Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report. 2021 , 12, 3273-3276	3
331	International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIa non-small-cell lung cancer. 2021 ,	3
330	Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer. 2021 ,	1
329	First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. 2021 , 6, 100273	17
328	USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma. 2021 , 10,	5
327	Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.. 2021 , 5, 1611-1624	1
326	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. 2021 , 31, 399-406	0

- 325 Long-term Pemetrexed Administration in 22 Patients with Non-small Cell Lung Cancer in a Japanese Phase II Randomized Study. **2009**, 49, 1019-1026
- 324 Individualization of treatment in non-small cell lung cancer. **2009**, 1, 1
- 323 Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. **2009**, 2, 251-60 1
- 322 Lung Cancer Resistance to Chemotherapy. **2010**, 331-393
- 321 Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment. **2010**, 177-194
- 320 Tumors of the Lung, Pleura, and Mediastinum. **2010**, 737-771 1
- 319 Abstract PL2-2: The genomic landscape in lung cancer. **2010**,
- 318 Lobectomy After Induction Therapy for Stage IIIA NSCLC in the Presence of Persistent N2 Disease. **2011**, 111-117
- 317 The Clinical Investigation of Pemetrexed Plus Carboplatin as an Active and Tolerable Treatment Plan in Chinese Elderly Patients with Advanced Lung Adenocarcinoma. **2011**, 02, 311-316
- 316 Evaluation of the Safety Profiles of Pemetrexed in Combination with Cisplatin for Malignant Pleural Mesothelioma in an Outpatient Clinic. **2011**, 51, 109-112
- 315 Adjuvant Therapy for Lung Cancer in the Elderly. **2011**, 497-503
- 314 Facteurs prédictifs pour un traitement personnalisé des cancers bronchiques non à petites cellules. **2011**, 103-125
- 313 Stratégie thérapeutique initiale dans les cancers bronchiques non à petites cellules. **2011**, 93-101
- 312 A Retrospective Study of Feasibility of Third-line or Higher Chemotherapy Using Pemetrexed in Non-squamous, Non-small Cell Lung Cancer Patients. **2011**, 51, 227-232
- 311 Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for Advanced and Pre-treated Non-Small-Cell Lung Cancer. **2011**, 321-329 4
- 310 Diagnostic, Prognostic, and Therapeutic Value of Gene Signatures in Non-Small Cell Lung Cancer. **2012**, 81-94
- 309 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 308 Targeted Therapies for Non-small-Cell Lung Cancer. **2012**, 93-114

- 307 A Case of Adenocarcinoma of the Lung Successfully Treated with Pemetrexed as Fourth-line Chemotherapy for Multiple Liver Metastases After Acquired Resistance to Crizotinib. **2012**, 52, 242-247
- 306 Unexpected Dramatic Response of Pretreated Invasive Thymic Malignancies on Pemetrexed-Case Report and Review of Current Treatment Modalities. **2012**, 02, 107-115
- 305 First-line therapy of advanced non-small cell lung cancer not harboring an activating EGFR mutation. **2012**, 59-74
- 304 Second-line therapy of non-small cell lung cancer. **2012**, 85-92
- 303 Treatment of small cell lung cancer. **2012**, 129-140
- 302 Predictive Markers in Lung Cancer. **2013**, 43-68
- 301 Markers in Lung Cancer. **2013**, 163-187 1
- 300 Lung Cancer. **2013**, 119-138
- 299 Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available to the Pulmonologist. **2013**, 261-270
- 298 A Case of Squamous Cell Carcinoma of the Lung Diagnosed During Long Term Pemetrexed Chemotherapy for Recurrent Large Cell Carcinoma of the Lung. **2013**, 53, 29-34
- 297 Histological Typing Accuracy Rate of Preoperative Bronchoscopic Cytology in Patients with Surgically Resected Lung Carcinoma. **2013**, 53, 220-226 1
- 296 Bone Therapy. **2013**, 643-652
- 295 Lung cancer and molecular targeted drugs. **2013**, 125, 57-66
- 294 The Case of a Patient with Non-small Cell Lung Cancer in Whom Periodic Testing for D-dimer Led to Early Detection of Pulmonary Embolus Caused by Bevacizumab and Early Initiation of Anticoagulation Therapy. **2013**, 39, 552-557 2
- 293 A case of complete resection of adenocarcinoma of the lung after chemotherapy using Carboplatin, Pemetrexed, and Bevacizumab. **2013**, 27, 826-831
- 292 Assessment of Diagnostic Accuracy of Bronchoalveolar Lavage Cytology in the Diagnosis of Lung Tumors and Contribution to the Classification of Non-Small Cell Lung Cancer Entities: A Retrospective Clinopathological Study. **2013**, 03, 107-112
- 291 Isolierte Thoraxperfusion mit Chemofiltration (ITP-F) beim fortgeschrittenen und vorbehandelten nicht kleinzelligen Bronchialkarzinom. **2013**, 403-411
- 290 Chemotherapy for the Lungs. **2013**, 607-616

- 289 Systemic Therapy for Lung Cancer. **2013**, 125-135
- 288 [Role of diagnostic imaging in thoracic surgery]. **2013**, 69, 427-33
- 287 Chemotherapy and molecularly targeted agents for advanced non-small-cell lung cancer. **2013**, 102-113
- 286 The Role of Phase III Trials in Modern Drug Development. **2014**, 763-783
- 285 Crizotinib in non-small cell lung cancer. **2014**, 03, 5-9
- 284 A Retrospective Study of Combination Chemotherapy with Cisplatin Plus Pemetrexed as a First-line Therapy for Advanced Non-squamous Non-small Cell Lung Cancer. **2014**, 54, 128-134
- 283 Investigation of Combining Serum Tumor Biomarkers and Clinical Features for Elderly Lung Cancer Diagnosis and Classification. **2014**, 05, 133-140
- 282 Maintenance Chemotherapy for Advanced Non-small Cell Lung Cancer. **2014**, 54, 887-891 1
- 281 Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung. **2014**, 05, 1012-1020 1
- 280 A Case of Left Axirally Lymph Node Metastasis Resected 25 Years after the Diagnosis of Stage IV Lung Cancer. **2014**, 75, 922-927
- 279 A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. **2014**, 15, 5941-4 9
- 278 Advances in Radiotherapy for Locally Advanced NSCLC. **2015**, 69-94
- 277 Adequacy and Tissue Preservation of Small Biopsy and Cytology Specimens. **2015**, 39-59
- 276 Current Status and Future Perspective on Cytotoxic Agents for Squamous Cell Carcinoma of the Lung. **2015**, 55, 973-981
- 275 Serum Protein Pattern Could Predict the Therapeutic Effect of First-Line Pemetrexed/Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma. **2015**, 6, 292-296
- 274 Lung Cancer. **2015**, 363-372
- 273 Lung Cancer: Diagnosis and Treatment Approach. **2015**, 97-144 2
- 272 Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation. **2015**, 06, 1214-1222

271 Therapy options for advanced NSCLC. **2015**, 5-25

270 Targeted Therapies for Non-Small Cell Lung Cancer. **2015**, 89-101

1

269 Pharmacology and Clinical Development of New Molecularly Targeted Agents. **2015**, 9-29

268 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

267 Non-small cell lung cancer and superior vena cava obstruction. **2015**, 11-24

266 Expectations in the care of lung cancer. **2015**, e420-4

265 Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers. **2015**, 16, 4791-5

4

264 Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. **2015**, 16, 5521-4

5

263 A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer. **2015**, 16, 5963-6

3

262 Lung. 203-220

261 Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Experience. **2015**, 16, 5899-902

1

260 Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. **2016**, 07, 455-463

259 Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for Advanced and Pretreated Non-small-cell Lung Cancer. **2016**, 487-495

258 Successful Pemetrexed Rechallenge Chemotherapy in Advanced Pulmonary Adenocarcinoma. **2016**, 56, 273-277

257 Identification of the Risk Factors for Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Chemotherapy. **2016**, 42, 278-285

256 Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer. **2016**, 90, 1-6

1

255 Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy. **2016**, 37, 242-250

1

254 Prospective Analysis of Patients Treated with Chemotherapy in Metastatic Adenocarcinoma of Lung Single Centre Experience. **2017**, 08, 838-844

- 253 Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience. **2017**, 54, 197-202 2
- 252 Predictive Factors of Severe Toxicities of Pemetrexed-Containing Chemotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer. **2017**, 08, 1030-1039
- 251 Clinical profile of nonsmall cell lung carcinoma patients treated in a single unit at a tertiary cancer care center. **2017**, 54, 193-196 2
- 250 First-line therapy outcomes in patients with advanced stage nonsmall cell lung cancer treated at nongovernment tertiary care center in India: Experience from a real world practice. **2017**, 54, 182-186 1
- 249 Metronomic chemotherapy with vinorelbine as the optimal treatment option in real clinical practice. **2017**, 6, 64
- 248 Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. **2017**, 6, S151-S157 1
- 247 PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer. **2017**, 1, 3-9
- 246 Multimodale und palliative Therapie des Lungenkarzinoms. **2018**, 205-211
- 245 Lung Cancer. **2017**,
- 244 Osimertinib - a new treatment option for patients with EGFR mutation T790M. **2017**, 11, 72-77
- 243 1. Treatment for Lung Cancer with Cytotoxic Agents -2017 Update-. **2017**, 106, 1089-1095
- 242 Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. **2017**, 8, 100754-100763 3
- 241 A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung Cancer. **2018**, 09, 314-322 1
- 240 Pathology of Lung Cancer. **2018**, 9-22
- 239 Lung Cancer. **2018**, 85-103
- 238 Present Situation and Progress of Lung Cancer Therapy. **2018**, 08, 837-843
- 237 Respiratory Organ Aging and Cancer. **2018**, 1-30
- 236 Superiority and Non-inferiority Phase III Oncology Trials. **2018**, 203-216

235 Non-Small Cell Lung Cancer: Therapeutic and Evolutionary Aspects in Cote d'Ivoire. **2018**, 07, 1-8

234 Management of Lung cancer. **2018**, 23-33

233 Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. **2018**, 39, 493

232 Thymidylate synthase maintains the de-differentiated state of aggressive breast cancers.

231 A clinical case of 3-year highly efficient pembrolizumab therapy of metastatic lung adenocarcinoma. **2018**, 9-10

1

230 Strategies for Progress. **2019**, 3-43

229 Treatment for Advanced Squamous Cell Carcinoma of the Lung. **2018**, 58, 325-330

228 Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +). **2018**, 68-72

227 Recent Progress and Prospects of Medical Therapy for Lung Cancer. **2018**, 77, 375-378

226 Non-small Cell Lung Cancer. **2019**, 143-192

225 New Insights into the Discovery of Novel Drugs to Treat Human Pulmonary Adenocarcinoma. **2019**, 10, 178-187

1

224 Histopathological Spectrum and Immunohistochemical Profile of Lung Carcinomas: A 9-Year Study from a Tertiary Hospital in North India. **2019**, 9, 169-175

2

223 Landmark Trials in Lung Cancer. **2019**, 41-74

222 Automated classification of histological subtypes of NSCLC using support vector machines with radiomic features. **2019**,

221 Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 $\geq 50\%$, but unanswered questions remain. **2019**, 7, S127

2

220 Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours. **2019**, 20, 2415-2420

1

219 The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma. **2019**, 7, 524

2

218 RETRACTED CHAPTER: Advances in Nanotechnology and Effects of Nanoparticles on Oxidative Stress Parameters. **2020**, 451-519

- 217 Recomendaciones de oncólogos que trabajan en el ISSSTE para el tratamiento sistémico del cáncer de pulmón avanzado 2020. **2020**, 2, 164-181
- 216 Malignant Epithelial Tumors of the Lung. **2020**, 317-400
- 215 Nanotechnological modifications of nanoparticles on reactive oxygen and nitrogen species. **2020**, 449-488
- 214 Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.. **2020**, 9, 7562-7571
- 213 Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. **2019**, 10, 6297-6307
- 212 Advances in the Treatment of Advanced Non-Small Cell Lung Cancer. **2020**, 09, 30-40
- 211 Respiratory Organ Aging and Cancer. **2020**, 215-244
- 210 A Case of Pulmonary Adenocarcinoma with Amylase Production. **2020**, 60, 48-53
- 209 Real-World Treatment Patterns of Lung Cancer in a Resource-Restricted Country: the Experience of Georgia. **2021**, 14, 11786329211055296
- 208 Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial. **2021**, 0
- 207 The Macrophage Reprogramming Ability of Antifolates Reveals Soluble CD14 as a Potential Biomarker for Methotrexate Response in Rheumatoid Arthritis. **2021**, 12, 776879 1
- 206 polymorphism as a predictive biomarker for gastrointestinal and hematological toxicity in North Indian adenocarcinoma patients. **2021**, 1-15 0
- 205 Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. **2021**, 44, 1271-1281 3
- 204 Intratumoral hyperthermic chemotherapy injection in peripheral non-small cell lung cancer. **2020**, 14,
- 203 Molecular pathology. 95-118 1
- 202 Can we expect progress from targeted therapy of SCLC?. 234-246
- 201 The incidence of lung cancer in the Moscow region from 1998 to 2018. **2020**, 30, 401-407
- 200 Morphological and molecular genetic diagnosis of lung cancer: methods and problems. **2020**, 7, 51-62 2

- 199 Real world efficacy of immunotherapy in nonsmall cell lung cancer. **2020**, 10, 5-20 0
- 198 New Strategies in the Treatment of Advanced Squamous Non-Small Cell Lung Cancer. **2020**, 60, 379-384
- 197 Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. **2011**, 36, 263-79 14
- 196 Targeting the tumor vascular supply with vascular disrupting agents. **2010**, 2, 192-3
- 195 Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?. **2010**, 2, 189-91 1
- 194 Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. **2011**, 3, 88-98 14
- 193 Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. **2010**, 10, 1-48 23
- 192 Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM. **2012**, 4, 214-6 16
- 191 Steatocystoma multiplex as initial impression of non-small cell lung cancer with complete response to gefitinib. **2014**, 26, E5-9
- 190 Retreatment with pemetrexed chemotherapy in advanced non-small cell lung cancer patient. **2014**, 6, 856-60 3
- 189 Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. **2014**, 7, 3833-42 4
- 188 Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma. **2014**, 26, 705-10 2
- 187 Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer care. **2014**, 6, 1888-91
- 186 Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?. **2015**, 3, 31 1
- 185 A strong step forward in maintenance therapy for non-small cell lung cancer treatment. **2012**, 1, 99-101
- 184 Personalized maintenance therapy in advanced non-small cell lung cancer. **2013**, 2, 452-6
- 183 The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer. **2015**, 7, 230-4 2
- 182 Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. **2015**, 5, 2229-40 5

- 181 Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma. **2015**, 8, 13716-23
- 180 Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. **2015**, 4, 704-12 7
- 179 [Prospect and Current Situation of Immune Checkpoint Inhibitors ?in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients]. **2017**, 20, 427-432
- 178 [Treatment of Advanced Squamous Cell Lung Cancer]. **2016**, 19, 687-691 3
- 177 [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma]. **2011**, 14, 704-9
- 176 [A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer]. **2011**, 14, 43-8 1
- 175 [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases]. **2011**, 14, 54-7 0
- 174 [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer]. **2012**, 15, 576-82 3
- 173 [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. **2012**, 15, 569-75 3
- 172 [Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer]. **2012**, 15, 179-82 1
- 171 [Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)]. **2014**, 17, 57-72 4
- 170 [Clinical significance of ERCC1, RRM1 and TS in non-small cell lung cancer]. **2014**, 17, 496-500 0
- 169 [Clinical investigation of efficacy of third-line and beyond pemetrexed treatment in advanced non-squamous non-small cell lung cancer]. **2012**, 15, 117-21 1
- 168 [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer]. **2014**, 17, 635-42 0
- 167 [Pemetrexed combined DDP in the treatment of advanced non-small cell lung cancer: a case report and literature review]. **2010**, 13, 755-8
- 166 [Analysis of prognostic factors in patients with stage IV lung adenocarcinoma after failure of second-line EGFR-TKIs therapy]. **2013**, 16, 38-42
- 165 Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan. **2010**, 13, 1009-15 3
- 164 Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung. **2017**, 8, 267-272

- 163 [Treatment choice for advanced non-small cell lung cancer patients who had gradual progression after EGFR-TKIs: 32 cases report]. **2013**, 16, 524-8
- 162 [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma]. **2013**, 16, 529-34
- 161 [Sequential Treatment of Advanced Squamous Lung Cancer: ?First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence]. **2015**, 18, 308-14
- 160 [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. **2010**, 13, 238-41
- 159 A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit. **2018**, 19, 2973-2978
- 158 [Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2019 Version)]. **2019**, 22, 187-207 3
- 157 Randomized phase II study of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic intensity-modulated radiation therapy in patients with stage IV lung adenocarcinoma. **2019**, 9, 1235-1245 3
- 156 [Clinical characteristics and risk factors affecting outcomes of elderly patients with non-small cell lung cancer complicated by chronic obstructive pulmonary disease]. **2017**, 37, 889-894
- 155 [Matrine inhibits proliferation and promotes autophagy and apoptosis in non-small cell lung cancer cells by deactivating PI3K/AKT/mTOR pathway]. **2019**, 39, 760-765 3
- 154 UBE2T silencing inhibited non-small cell lung cancer cell proliferation and invasion by suppressing the wnt/?atenin signaling pathway. **2017**, 10, 9482-9488 11
- 153 [Chinese Experts Consensus on Immune Checkpoint Inhibitors ?for Non-small Cell Lung Cancer (2020 Version)]. **2021**, 24, 217-235 1
- 152 [Review on the Combination Strategy of Anti-angiogenic Agents ?and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer]. **2021**, 24, 357-364
- 151 Recent advances in early stage lung cancer. **2021**, 7, 163-174 2
- 150 [Comprehensive Treatment of An Advanced Lung Cancer Patient with ?EGFR Driver Gene Positive]. **2021**, 24, 447-452
- 149 Circulating Levels of Monocytic Myeloid-Derived Suppressor Cells (M-MDSC) and CXCL-8 in Non-Small Cell Lung Cancer (NSCLC). **2021**, 20, 15-21 1
- 148 Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. **2021**, 20, 15330338211039676 0
- 147 Pyrotinib in Patients with -Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. **2021**, 5
- 146 Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. **2021**, 23, 369-402 3

- 145 Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.. **2021**, 164, 84-90
- 144 Under the Magnifying Glass: Searching for The Evidence of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer. **42**,
- 143 Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. **2021**, 57, 0
- 142 Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study. **2021**, 12, 727102
- 141 Identification of Clinical and Tumor Microenvironment Characteristics of Hypoxia-Related Risk Signature in Lung Adenocarcinoma. **2021**, 8, 757421 1
- 140 Nicht-kleinzelliges Lungenkarzinom: Wandel und Möglichkeiten der molekularen Diagnostik.
- 139 Epidemiological, clinical profile, and treatment outcome of stage iv nonsquamous non-small cell lung cancer patients presenting to tertiary care hospital in North India. **2021**, 5, 104
- 138 Prevalence and Clinicopathologic Risk Factors for Epidermal Growth Factor Receptor, Anaplastic Lymphoma Kinase, and ROS-1 Fusion in Metastatic Non-small Cell Lung Carcinoma. **2021**,
- 137 Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise.. **2022**, 12, 3
- 136 Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.. **2022**, 0
- 135 Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology.. **2021**, 11, 788245
- 134 Clinical Characteristics and Outcomes in Advanced -Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005).. **2022**, 3, 100261 0
- 133 Lungenkarzinom: Mehr Optionen für Patienten im fortgeschrittenen Stadium.
- 132 The anti-programmed cell death 1 antibody immunotherapy: A paradigm shift in the treatment of non-small-cell lung cancer. **2020**, 5, 29
- 131 Ability of the Glasgow Prognostic Score to predict the tolerability and efficacy of platinum-combination chemotherapy among elderly patients with advanced non-small cell lung cancer. **2021**, 68, 260-264 1
- 130 Prognostic Implications of Pyroptosis-Related Gene Signatures in Lung Squamous Cell Carcinoma.. **2022**, 13, 806995 0
- 129 Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.. **2022**, 1, CD013453 0
- 128 Comparative efficacy of 10 Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC a systematic review and network meta-analysis.. **2022**, 13, 465-480 0

- 127 Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy.. **2022**, 14, 17588359211065152
- 126 Clinical Features, Treatments, and Prognosis of Intramedullary Spinal Cord Metastases From Lung Cancer: A Case Series and Systematic Review.. **2022**, ○
- 125 Targeting un-MET needs in advanced non-small cell lung cancer.. **2021**, 164, 56-68 1
- 124 Terelizumab Combined with Hypofractionated Radiation Therapy and GM-CSF as Dyspnea with Stage IV Lung Squamous Cell Carcinoma: A Case Report.
- 123 Global trends of researches on bone metastasis: A bibliometric and visualization study.. **2022**, 101, e28761 ○
- 122 Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.. **2022**, 1 ○
- 121 A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients.. **2022**, 21, 15347354221083968 1
- 120 A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer.. **2022**, 21, 15330338221078429 ○
- 119 Neurological complications of lung cancer. **2022**, 243-276
- 118 Challenges in the Use of Targeted Therapies in NSCLC.. **2022**, 1
- 117 The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation.. **2022**, 10, ○
- 116 Pancreatic head pancreatic body/tail cancer: Are they different?. **2022**, 14, 716-723
- 115 Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.. **2022**, 12, 821391 ○
- 114 Immunogenomic profiling of lung adenocarcinoma reveals high-grade growth patterns are associated with an immunogenic tumor microenvironment.
- 113 Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung.. **2022**, 1
- 112 Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update.. **2022**, 14, ○
- 111 Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis.. **2022**, 3, 100322 ○
- 110 Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.. **2022**, 166, 114-121 ○

109	Anti-cancer peptide-based therapeutic strategies in solid tumors.. 2022 , 27, 33	2
108	A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.. 2022 , 20, 158	0
107	Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis.. 2021 , 100, e27954	1
106	Systematic review and meta-analysis of the predictive power of polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients. 2021 , 1-11	0
105	Image_1.pdf. 2020 ,	
104	Image_1.TIF. 2020 ,	
103	Image_2.TIF. 2020 ,	
102	Image_3.TIF. 2020 ,	
101	Image_4.TIF. 2020 ,	
100	Image_5.TIF. 2020 ,	
99	Data_Sheet_1.docx. 2020 ,	
98	Image_1.TIF. 2018 ,	
97	Image_2.TIF. 2018 ,	
96	Image_3.TIF. 2018 ,	
95	Image_4.TIF. 2018 ,	
94	Image_5.TIF. 2018 ,	
93	Image_6.TIF. 2018 ,	
92	Image_7.TIF. 2018 ,	

91 Table_1.XLSX. 2018,

90 Table_2.XLSX. 2018,

89 Data_Sheet_1.docx. 2020,

88 Image_1.tif. 2020,

87 Image_2.tif. 2020,

86 Image_3.tif. 2020,

85 Image_4.tif. 2020,

84 Image_5.tif. 2020,

83 Image_6.tif. 2020,

82 Table_1.docx. 2020,

81 DataSheet_1.docx. 2021,

80 Image_1.tiff. 2021,

79 Image_2.tiff. 2021,

78 Image_3.tiff. 2021,

77 Table_1.docx. 2019,

76 Table_2.docx. 2019,

75 Predictive significance of inflammatory indexes in metastatic nonsmall cell lung cancer patients treated with platinum-doublet chemotherapy.. 2022, 18, 220-223

o

74 Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease. 2022, 19, 14-19

73	Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. 2022 , 20, 497-530	24
72	Clinical-molecular prospective cohort study in Non-Small Cell Lung Cancer (PROMOLE study): a comprehensive approach to identify new predictive markers of pharmacological response. 2022 ,	0
71	A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).. 2022 ,	
70	Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. 2022 , 107, 1243-1263	2
69	Treatment of drug-induced immune thrombocytopenias. 2022 , 107, 1264-1277	3
68	Hospital case-volume and mortality after lung cancer surgery: A population-based retrospective cohort study. 2022 , 169, 61-66	
67	LncRNA HAR1A Suppresses the Development of Non-Small Cell Lung Cancer by Inactivating the STAT3 Pathway. 2022 , 14, 2845	0
66	Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).	1
65	Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. 2022 , 12, 815	0
64	ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance. 1-13	0
63	Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis. 2022 , 12, e057098	0
62	Correlations between Objective Response Rate and Survival-based Endpoints in First-line Advanced Non-Small Cell Lung Cancer: a Systematic Review and Meta-analysis. 2022 ,	0
61	Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study. 2022 , 13, 204062232211083	0
60	Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. 2022 , 14, 3362	
59	Clinically-meaningful improvements in therapy for unresectable NSCLC.	0
58	Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. 2015 , 44, 449-462	2
57	Immune checkpoint inhibitors in extensiv-stage small-cell lung cancer. 2022 ,	0
56	PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.	1

55	Cuproptosis predicts the risk and clinical outcomes of lung adenocarcinoma. 12,	0
54	Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: a post hoc efficacy analysis of KEYNOTE-189. 2022 , 100389	
53	Tumor mutational burden and efficacy of chemotherapy in lung cancer.	
52	Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial. 2022 ,	1
51	Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. 2022 , 172, 19-28	1
50	Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. 2022 , 7, 100560	
49	Bench to bedside: recent advances in lung cancer pathological research with implications for diagnostic clinical practice. 2022 ,	0
48	Polypharmacology in Clinical Applications Anticancer Polypharmacology. 2022 , 73-132	0
47	Chemotherapy for Lung Cancer. 2022 ,	0
46	Protective roles of cytoplasmic p21 Cip1 /Waf1 in senolysis and ferroptosis of lung cancer cells.	1
45	Non-small cell lung cancer in China.	3
44	Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. 2022 , 114, 278-287	0
43	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. 2022 , 14, 4481	0
42	Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis. 13,	0
41	The Management of Oligometastases in Non-small Cell Lung Cancer Is Stereotactic Ablative Radiotherapy now Standard of Care?. 2022 ,	0
40	Chemotherapeutic Protocols for the Treatment of Lung Cancer. 2022 , 291-305	0
39	Phase I trial of the TNF- α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. 2022 , 13,	1
38	Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSg) 1302.	0

37	Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations. Volume 15, 1197-1210	0
36	Folate Antagonists. 1-11	0
35	Cancer of the Lung. 1-29	0
34	Infections virales chroniques (hépatites, VIH) et impact sur le choix thérapeutique. 2022 , 14, 2S351-2S357	0
33	Drug Resistance in Lung Cancer. 2022 ,	0
32	Immunocytochemical evaluation of TTF-1, Napsin-A, and p-63 for Subtyping of Non-Small Cell Lung Carcinoma and Clinicopathological Correlation. 2022 , 39, 180	0
31	Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. 2017 , 46, 333-338	3
30	Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors. 2022 , 100917	1
29	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. 2022 ,	0
28	A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer. 2022 , 101, e31751	0
27	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. 2022 , 24, 269-304	0
26	The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-III B Lung Squamous Cell Carcinoma.	0
25	Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. 12,	0
24	Metabolic reprogramming of cancer as a therapeutic target. 2022 , 130301	0
23	Neurogenic orthostatic hypotension after treatment with sorafenib. 2022 , 15, e247140	0
22	Unveiling the gemcitabine drug complexation with cucurbit[n]urils (n=6-8): A computational analysis.	0
21	Tumour Genetics and Genomics to Personalise Cancer Treatment. 2011 , 40, 362-368	0
20	CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarH-like homeobox 2 axis. Publish Ahead of Print,	0

- 19 Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer. **2023**, 12, 137 ○
- 18 Circ_0110498 facilitates the cisplatin resistance of non-small cell lung cancer by mediating the miR-1287-5p/RBBP4 axis. ○
- 17 Alvopem[®] (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance. **2023**, 16, ○
- 16 Unveiling the gemcitabine drug complexation with cucurbit[n]urils (n = 6B): a computational analysis. ○
- 15 Multiple cardiotoxicities during osimertinib therapy. 107815522311643 ○
- 14 Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. **2023**, 68, 100960 ○
- 13 The pharmacological and biological importance of EZH2 signaling in lung cancer. **2023**, 160, 114313 ○
- 12 Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. 11, ○
- 11 Cytological characteristics of histological types of lung cancer by cytomorphometric and flow cytometric analyses using liquid-based cytology materials. ○
- 10 Lung cancer in the emergency department. **2023**, 2, ○
- 9 Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. **2023**, 6, e232002 ○
- 8 NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know. **2023**, 13, 1117 ○
- 7 Using an In-Sample Addition of Medronic Acid for the Analysis of Purine- and Pyrimidine-Related Derivatives and Its Application in the Study of Lung Adenocarcinoma A549 Cell Lines by LCMS/MS. ○
- 6 Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study. 14, ○
- 5 Rigid Bronchoscopy with Y Stent Insertion at Left Secondary Carina. **2012**, 291-298 ○
- 4 HER2 exon 20 insertion mutations and myelosuppression in lung adenocarcinoma patient: a case report and response to trastuzumab deruxtecan. **2023**, 18, ○
- 3 Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. **2023**, ○
- 2 Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort. 56, ○

- 1 Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan. 1-45

o